<SEC-DOCUMENT>0001401914-21-000015.txt : 20210107
<SEC-HEADER>0001401914-21-000015.hdr.sgml : 20210107
<ACCEPTANCE-DATETIME>20210107160553
ACCESSION NUMBER:		0001401914-21-000015
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210107
DATE AS OF CHANGE:		20210107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Dare Bioscience, Inc.
		CENTRAL INDEX KEY:			0001401914
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				204139823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-251599
		FILM NUMBER:		21514254

	BUSINESS ADDRESS:	
		STREET 1:		3655 NOBEL DRIVE
		STREET 2:		SUITE 260
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-926-7655

	MAIL ADDRESS:	
		STREET 1:		3655 NOBEL DRIVE
		STREET 2:		SUITE 260
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cerulean Pharma Inc.
		DATE OF NAME CHANGE:	20090714

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tempo Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070604
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>a424b32021_0107lpcprospect.htm
<DESCRIPTION>424B3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib7f856a4ed56410bb70efd9cb345751c_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Filed Pursuant to Rule 424(b)(3)</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registration No. 333-251599</font></div><div style="margin-top:5pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PROSPECTUS</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dar&#233; Bioscience, Inc.</font></div><div style="margin-bottom:6pt;text-align:center"><img alt="darebioinlinefullcolorrgbaa.jpg" src="darebioinlinefullcolorrgbaa.jpg" style="height:108px;margin-bottom:5pt;vertical-align:text-bottom;width:269px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,380,126 Shares of Common Stock</font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus relates to the offer and sale or other disposition of up to 6,380,126 shares of our common stock, par value $0.0001, by Lincoln Park Capital Fund, LLC, or Lincoln Park or the selling stockholder.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of common stock being offered by Lincoln Park have been or may be issued pursuant to the purchase agreement dated April&#160;22, 2020 that we entered into with Lincoln Park, which we refer to in this prospectus as the Purchase Agreement. See &#8220;Our Agreements with Lincoln Park&#8221; for a description of that agreement and &#8220;Selling Stockholder&#8221; for additional information regarding Lincoln Park. The prices at which Lincoln Park may sell the shares will be determined by the prevailing market price for the shares or in negotiated transactions.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholder.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We filed a registration statement on Form S&#8211;1 (File No. 333-237954) with the Securities and Exchange Commission on May 1, 2020 that was declared effective on May 12, 2020, which we refer to in this prospectus as the Prior Registration Statement. The Prior Registration Statement registered 7,500,000 shares of our common stock that have been or may be issued pursuant to the Purchase Agreement, of which 130,126 shares remain registered and unsold thereunder as of January 4, 2021. Such registered and unsold shares of common stock are being carried over from the Prior Registration Statement and are being offered and sold under this prospectus pursuant to Rule 429 under the Securities Act of 1933, as amended, or the Securities Act. In addition, 6,250,000 shares of our common stock, which were not registered under the Prior Registration Statement, are being offered and sold under this prospectus.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The selling stockholder may sell or otherwise dispose of the shares of common stock described in this prospectus in a number of different ways and at varying prices. See &#8220;Plan of Distribution&#8221; beginning on page 25 of this prospectus for more information about how and the prices at which the selling stockholder may sell or otherwise dispose of the shares of our common stock being offered. The selling stockholder is an &#8220;underwriter&#8221; within the meaning of Section 2(a)(11) of the Securities Act.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The selling stockholder will pay all brokerage fees and commissions and similar expenses. We will pay all expenses (except brokerage fees and commissions and similar expenses) relating to the registration of the shares with the Securities and Exchange Commission.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;DARE.&#8221; On January 5, 2021, the last reported sale price of our common stock was $1.39 per share. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investing in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should consider carefully the risks described under the caption &#8220;Risk Factors&#8221; beginning on page 10 of this prospectus, and under similar headings in the documents incorporated by reference in this prospectus, as well as in any amendments or supplements to this prospectus.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.  Any representation to the contrary is a criminal offense.</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:440.25pt"><tr><td style="width:1.0pt"></td><td style="width:207.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:159.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The date of this prospectus is January&#160;7, 2021</font></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div><div id="ib7f856a4ed56410bb70efd9cb345751c_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.00pt"><tr><td style="width:1.0pt"></td><td style="width:430.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_7" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">About This Prospectus</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_7" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">1</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_10" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Prospectus Summary</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_10" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_13" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Risk Factors</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_13" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">10</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_16" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Special Note Regarding Forward-Looking Statements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_16" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">14</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_19" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Our Agreements with Lincoln Park</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_19" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">16</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_22" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Use of Proceeds</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_22" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">20</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_25" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Selling Stockholder</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_25" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">21</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_28" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Dilution</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_28" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">22</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_31" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Plan of Distribution</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_31" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">24</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_541" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Executive and Director Compensation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_541" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">25</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_34" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Legal Matters</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_34" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">30</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_37" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Experts</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_37" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">30</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_40" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Where You Can Find More Information</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_40" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">31</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_43" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Incorporation of Documents by Reference</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ib7f856a4ed56410bb70efd9cb345751c_43" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">31</a></font></div></td></tr></table></div><div style="margin-bottom:5pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">i</font></div><div style="margin-bottom:10pt"><font><br></font></div></div></div><div id="ib7f856a4ed56410bb70efd9cb345751c_7"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:45.00pt 54.00pt 45.00pt 54.00pt"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:138%">ABOUT THIS PROSPECTUS</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus does not contain all of the information included in the registration statement of which this prospectus forms a part. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits. You should carefully read this prospectus, any prospectus supplement or free writing prospectus that we subsequently authorize for use in connection with this offering, the information and documents incorporated herein by reference and the additional information under the heading &#8220;Where You Can Find More Information&#8221; before making an investment decision. You should rely only on the information we have provided or incorporated by reference in this prospectus, or in any prospectus supplement or free writing prospectus that we subsequently authorize for use in connection with this offering. Neither we, nor the selling stockholder, have authorized anyone to provide you with information different from that contained or incorporated by reference in this prospectus.  If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information in this prospectus, or any related prospectus supplement or free writing prospectus, is accurate only as of the date on the front of the document and that any information we have incorporated herein by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, or such prospectus supplement or free writing prospectus, or any sale of a security. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither we, nor the selling stockholder, are offering to sell or seeking offers to purchase these securities in any jurisdiction where the offer or sale is not permitted. We have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities hereunder and the distribution of this prospectus outside the United States. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made.  Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate, including our general expectations and market position, market opportunity and market size, is based on information from various sources, including peer reviewed journals, formal presentations at medical society meetings and third-parties commissioned by us or our licensors to provide market research and analysis, and is subject to a number of assumptions and limitations. Although we are responsible for all of the disclosure contained in this prospectus and we believe the information from industry publications and other third-party sources included in this prospectus is reliable, such information is inherently imprecise. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section captioned &#8220;Risk Factors.&#8221; </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent there are inconsistencies between this prospectus, any related prospectus supplement or free writing prospectus, and any documents incorporated by reference, the document with the most recent date will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, &#8220;Dar&#233;,&#8221; &#8220;Dar&#233; Bioscience,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms refer to Dar&#233; Bioscience, Inc. and its subsidiaries.</font></div></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">1</font></div></div></div><div id="ib7f856a4ed56410bb70efd9cb345751c_10"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:45.00pt 54.00pt 45.00pt 54.00pt"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:138%">PROSPECTUS SUMMARY</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This summary highlights information contained elsewhere in this prospectus. This summary provides an overview of selected information and does not contain all of the information you should consider before investing in our securities. We urge you to read this entire prospectus, including our consolidated financial statements, notes to the consolidated financial statements, the information in the section captioned &#8220;Risk Factors,&#8221; and other information incorporated herein by reference to our other filings with the Securities and Exchange Commission, or SEC, or included in any applicable prospectus supplement. </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">About Dar&#233; Bioscience</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company committed to the acceleration of innovative products for women&#8217;s health. We are driven by a mission to identify, acquire and develop a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, fertility, and sexual and vaginal health. Our business strategy is to in-license or otherwise acquire the rights to differentiated product candidates in our areas of focus, some of which have existing clinical proof-of-concept data, to take those candidates through mid- to late-stage clinical development, and to establish and leverage strategic partnerships to achieve commercialization.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since July 2017, we have assembled a portfolio of clinical-stage and pre-clinical-stage candidates. While we will continue to assess opportunities to expand our portfolio, our current focus is on advancing our existing product candidates through mid- and late stages of clinical development or approval. Our portfolio includes three product candidates in advanced clinical development&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">DARE-BV1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a novel thermosetting bioadhesive hydrogel formulated with clindamycin phosphate 2% to be administered in a single vaginally delivered application, as a first line treatment for bacterial vaginosis&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Ovaprene&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a hormone-free, monthly vaginal contraceptive&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Sildenafil Cream, 3.6%</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a proprietary cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio also includes three product candidates in Phase 1 clinical development or that we believe are Phase 1-ready&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">DARE-HRT1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a combination bio-identical estradiol and progesterone intravaginal ring for the treatment of menopausal symptoms, including vasomotor symptoms, as part of a hormone replacement therapy following menopause&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">DARE-FRT1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">DARE-VVA1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our portfolio includes these pre-clinical stage product candidates&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">DARE-LARC1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a combination product designed to provide long-acting, reversible contraception comprising an implantable, user-controlled wireless drug delivery system and levonorgestrel&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">ORB-204 and ORB-214</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, injectable formulations of etonogestrel designed to provide contraception over 6-month and 12-month periods, respectively&#59; and</font></div></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:45.00pt 54.00pt 45.00pt 54.00pt"><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">DARE-RH1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a novel approach to non</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hormonal contraception for both men and women by targeting the CatSper ion channel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary operations have consisted of, and are expected to continue to consist of, product research and development and advancing our portfolio of product candidates through clinical development and regulatory approval. To date, we have not obtained any regulatory approvals for any of our product candidates, commercialized any of our product candidates or generated any product revenue. The majority of our development expenses incurred during the fourth quarter of 2020 and that we expect to incur in 2021 will support the advancement of DARE-BV1, Ovaprene and Sildenafil Cream, 3.6%.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect of the COVID-19 pandemic and efforts to reduce the spread of COVID-19 remain a rapidly evolving and uncertain risk to our business, operating results, financial condition and stock price. In November 2020, the U.S. began to experience a substantial surge in cases and hospitalizations and intensive care unit capacity became strained. States and counties across the country imposed or re-imposed stay-at-home orders and shutdowns of non-essential businesses in efforts to reduce spread of the disease. In December 2020, the U.S. Food and Drug Administration (FDA) issued the first emergency use authorization for a vaccine for the prevention of COVID-19. However, experts have cautioned it is unlikely that an authorized vaccine will be available to a significant proportion of people in the U.S. before late spring or early summer 2021, and the timeline for the pandemic and its associated restrictions to end remain uncertain. Given the high level of uncertainty regarding the duration and impact of the pandemic on the U.S. and global economies, workplace environments and capital markets, we are unable to assess the full extent of the effects of the pandemic on our business. These effects could have a material adverse impact on our business, operating results and financial condition, including, without limitation, by adversely impacting our ability to raise capital when needed or on terms favorable or acceptable to us and increasing the anticipated aggregate costs and timelines for the development and marketing approval of our product candidates. For further discussion of risks and uncertainties related to the COVID-19 pandemic, see the risk factor titled, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic and efforts to reduce the spread of COVID-19 could negatively impact our business, including by increasing the cost and timelines for our clinical development programs,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 1A. Risk Factors of the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 that is incorporated by reference into this prospectus, as well as any risk factor similarly subcaptioned in any document subsequently incorporated by reference into this prospectus or any amendment or supplement to this prospectus</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Development</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2020, we announced positive topline results from our DARE-BVFREE Phase 3 clinical trial of DARE-BV1 for the treatment of bacterial vaginosis. As further discussed below, the study met its primary endpoint, demonstrating that a single administration of DARE-BV1 was superior to placebo as a primary therapeutic intervention for women diagnosed with bacterial vaginosis.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DARE-BVFREE was a randomized, multicenter, double-blind, placebo-controlled study that randomized 307 women diagnosed with bacterial vaginosis at 32 centers across the United States in a 2&#58;1 ratio to receive a single vaginal dose of DARE-BV1 (clindamycin phosphate vaginal gel, 2%) (N&#61;204) or a single vaginal dose of placebo gel (HEC Universal Placebo Gel) (N&#61;103) to be applied intravaginally within one day of randomization. Subjects were evaluated during three clinic visits&#58; Day 1 (screening and randomization visit), Day 7-14 (assessment visit that occurred 7 to 14 days after study drug administration), and Day 21-30 (test-of-cure visit that occurred 21 to 30 days after study drug administration).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoint for the study was clinical cure of bacterial vaginosis determined at the Day 21-30 visit in the modified intent-to-treat (mITT) study population (N&#61;180). In accordance with FDA guidance, the mITT population excludes subjects from the intent-to-treat (ITT) population (N&#61;307) who subsequently demonstrated a positive test result for other concomitant vaginal or cervical infections at baseline. Clinical cure was defined as resolution of the specific clinical signs that comprise the Amsel criteria&#59; specifically, resolution of abnormal vaginal discharge associated with bacterial vaginosis, clue cells less than 20% of total epithelial cells on microscopy, and a negative 10% KOH &#8220;whiff&#8221; test. The total study duration was approximately one month for each individual subject.</font></div></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:45.00pt 54.00pt 45.00pt 54.00pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DARE-BV1 demonstrated statistically significant efficacy in the primary endpoint and in all five pre-specified secondary efficacy assessments. The clinical cure endpoint results are shown in the following table&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:468.00pt"><tr><td style="width:1.0pt"></td><td style="width:230.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:112.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:114.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summary of Clinical Cure Results (mITT Population), p-value &#60; 0.001</font></td></tr><tr style="height:23pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DARE-BV1<br>(N &#61; 121)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Placebo<br>(N &#61; 59)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical Cure at Day 7-14 visit</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76.0%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23.7%</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical Cure at Day 21-30 visit (primary endpoint)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70.2%<br></font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35.6%</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical cure rate at the Day 21-30 visit for the ITT population was similar to that for the mITT population (70.1% for the DARE-BV1 group (N&#61;204) and 36.9% for the placebo group (N&#61;103), p-value &#60; 0.001).</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DARE-BV1 was well-tolerated in the study. There were no early discontinuations due to adverse events (AEs), and the only serious AE occurred in a woman in the placebo group. In the DARE-BV1 group, 15.3% of patients reported AEs that were considered to be possibly, probably or definitely related to study treatment compared to 9.7% of patients in the placebo group. Only two AEs were reported by more than 2% of patients in the DARE-BV1 arm and at a rate higher than in patients in the placebo arm &#8211; vulvovaginal candidiasis, commonly called a vaginal yeast infection (17.2% in the DARE-BV1 group and 3.9% in the placebo group), and vulvovaginal pruritus, commonly referred to as vaginal itching (4.4% in the DARE-BV1 group and 1.9% in the placebo group). Over half of the vaginal yeast infections reported in the DARE-BV1 group and exactly half of those reported in the placebo group occurred in patients who exhibited a positive yeast culture prior to dosing.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the topline results from the DARE-BVFREE study, we expect to have a pre-NDA meeting with the FDA in early 2021 and to submit a new drug application (NDA) to the FDA during the first half of 2021. DARE-BV1 received both Fast Track and Qualified Infectious Disease Product designations from the FDA for the treatment of bacterial vaginosis. Given these designations, the NDA could be eligible for priority review, which, if granted, could allow for a FDA review period of six months. Assuming a six-month review period and an approval from the FDA in 2021, we would expect a commercial launch of DARE-BV1 in the United States in early 2022.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. Before deciding whether to purchase our common stock, you should carefully consider the risks and uncertainties described in the section captioned &#8220;Risk Factors&#8221; in this prospectus, and under similar headings in the documents incorporated by reference into this prospectus, as well as in any amendments or supplements to this prospectus. The occurrence of any of these risk factors could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment in our common stock. These risk factors include, but are not limited to, the following&#58;</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to raise additional capital to continue our operations and remain a going concern, and our ability to do so may be limited and more expensive due to our low public float, low market capitalization, limited operating history and lack of revenue, and&#47;or applicable laws and regulations.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a limited operating history, have incurred significant losses since our inception and expect to continue to incur losses for the foreseeable future, which, together with our limited financial resources, makes it difficult to assess our prospects. </font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic and efforts to reduce the spread of COVID-19 could negatively impact our business, including by increasing the cost and timelines for our clinical development programs.</font></div></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:45.00pt 54.00pt 45.00pt 54.00pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not receive any additional payments under our license agreement with Bayer, and Bayer may terminate the agreement at any time without cause upon limited prior notice.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Due in part to our limited financial resources, we may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable indications or therapeutic areas for our product candidates, we may be unable to pursue and complete the clinical trials we would like to pursue and complete, and we may be unable to commence or complete clinical trials in accordance with our current timeline expectations.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a relatively small number of employees and if we fail to attract and retain key personnel, we may not successfully complete development of, obtain regulatory approval for or commercialize our product candidates, or otherwise implement our business plan.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cyber-attacks, security breaches, loss of data and other disruptions to our information technology systems or those of our third-party service providers could compromise sensitive information related to our business, delay or prevent us from accessing critical information or expose us to liability, any of which could adversely affect our business and our reputation.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend heavily on the success of our clinical-stage product candidates, DARE-BV1, Ovaprene and Sildenafil Cream, 3.6%. Clinical development is a lengthy and expensive process with an inherently uncertain outcome. Failure to successfully develop and obtain regulatory approval to market and sell any of these product candidates on our anticipated timelines, or at all, could have a materially adverse effect on our business, operating results and financial condition.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend highly on our license agreements for our clinical-stage product candidates and the loss or impairment of our rights under any license could have a materially adverse effect on our business prospects, operations and viability.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on, and intend to continue to rely on, third parties for the execution of significant aspects of our development programs, including the conduct of our clinical and non-clinical studies and the supply and manufacture of our product candidates. Failure of these third parties, including multiple single source suppliers and manufacturers, to successfully carry out their contractual duties, comply with regulatory requirements and applicable law, or meet expected deadlines may cause significant delays in our product development timelines and&#47;or failure of our programs.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data, and others, including regulatory authorities, may not agree with our interpretation of study data.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business depends on obtaining the approval of regulatory authorities, and in particular, FDA approval, for our product candidates in a timely manner, and the requirements for obtaining approval for our product candidates may change over time, requiring more financial resources and development time than we currently anticipate.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business strategy is to establish and leverage strategic partnerships to achieve commercialization of our product candidates, if approved. We have no internal sales, marketing or distribution capabilities. Under any such collaborations, we may not have control over several key elements relating to the development and commercialization of our product candidates, and any failure by such third parties to adequately perform their obligations under our agreements could negatively impact our business, operating results and financial condition.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The product candidates we are developing or may develop are likely to face significant competition. If we receive marketing approval for any of our product candidates, their ability to compete and potential to generate revenue will be impacted by the efficacy and safety outcomes of our clinical trials, the label claims that the FDA or other regulatory authorities approve for the product, and the degree of acceptance among the medical community and consumers and their preference of our products over available alternative products.</font></div></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:45.00pt 54.00pt 45.00pt 54.00pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we obtain regulatory approval in the United States or elsewhere to market any of our products, the reimbursement environment at the time of approval may hurt our financial prospects. If the out-of-pocket costs for our products are deemed by women to be high, a commercial market may never develop.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our failure to adequately protect or enforce our and our licensors&#8217; intellectual property rights could materially harm our proprietary position in the marketplace or prevent or impede the commercialization of our current and potential future products.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lack of patent protection for the active ingredients in certain of our product candidates, including DARE-BV1 and Sildenafil Cream, 3.6%, may limit the commercial opportunity for those products if competitors are able to develop and commercialize safe and effective alternative formulations or methods of delivery of the active ingredients. </font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The price of our common stock may be volatile and could subject us to securities litigation, including class-action lawsuits.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There is no assurance that we will continue satisfying the listing requirements of the Nasdaq Capital Market, and such failure could result in the suspension or delisting of our common stock, which could, among other things, substantially impair our ability to raise additional capital and have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The sale of our common stock to Lincoln Park may cause dilution to our other stockholders and the subsequent sale of the shares of common stock acquired by Lincoln Park, or the perception that such sales may occur, could cause the price of our common stock to fall.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There may be future sales or other dilution of our equity, including sales and issuances of our common stock under our ATM sales agreement and upon exercise of stock options and warrants, which may adversely affect the market price of our common stock, even if our business is doing well.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Information</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information related to our business and operations, please refer to the annual and quarterly reports incorporated herein by reference, as described under the caption &#8220;Incorporation of Documents by Reference&#8221; on page 31 of this prospectus.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Information</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 3655 Nobel Drive, Suite 260, San Diego, California 92122, and our telephone number at that address is (858) 926-7655. We maintain a website at www.darebioscience.com, to which we regularly post copies of our press releases as well as additional information about us.  The information contained on, or that can be accessed through, our website is not a part of this prospectus.  We have included our website address in this prospectus solely as an inactive textual reference.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dar&#233; Bioscience&#174; is a registered trademark of Dar&#233; Bioscience, Inc. Ovaprene&#174; is a registered trademark licensed to Dar&#233; Bioscience, Inc. All brand names or trademarks appearing in this prospectus are the property of their respective holders.  Use or display by us of other parties&#8217; trademarks, trade dress, or products in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owners.</font></div></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:45.00pt 54.00pt 45.00pt 54.00pt"><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Offering</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus relates to the resale by Lincoln Park Capital Fund, LLC, the selling stockholder identified in this prospectus, of shares of our common stock, par value $0.0001 per share, as follows&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.971%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock offered by the selling stockholder</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 6,380,126 shares, which includes 130,126 shares outstanding as of the date of this prospectus</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock outstanding prior to this offering</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,596,253 shares</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock to be outstanding after giving effect to the issuance of 6,250,000 shares under the Purchase Agreement offered under this prospectus that are not outstanding as of the date of this prospectus</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,846,253 shares</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Use of proceeds</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will receive no proceeds from the sale of shares of common stock by Lincoln Park in this offering.  We may receive up to approximately $7.0 million in aggregate gross proceeds from sales we make to Lincoln Park on or after the date of this prospectus under the Purchase Agreement. Any such proceeds we receive will be used for working capital and general corporate purposes. See &#8220;Use of Proceeds&#8221; on page 20 of this prospectus.</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk factors</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in our common stock involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page 10 of this prospectus, as well as the other information included in or incorporated by reference in this prospectus, for a discussion of risks you should carefully consider before investing in our common stock.<br></font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market symbol</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;DARE&#8221;</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actual number of shares of our common stock outstanding after this offering will vary depending on the actual number of shares we sell to Lincoln Park under the Purchase Agreement after the date of this prospectus. The number of shares of our common stock outstanding prior to and after this offering in the table above is based on 41,596,253 shares outstanding as of January&#160;4, 2021, and excludes&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2,786,591 shares of common stock issuable upon exercise of stock options outstanding as of January&#160;4, 2021, with a weighted-average exercise price of $1.16 per share&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2,168,366 shares of common stock reserved and available for future issuance as of January&#160;4, 2021 under our Amended and Restated 2014 Stock Incentive Plan&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1,908,643 shares of common stock issuable upon exercise of warrants outstanding as of January&#160;4, 2021, with a weighted-average exercise price of $1.41 per share.</font></div></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:45.00pt 54.00pt 45.00pt 54.00pt"><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Agreement with Lincoln Park </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;22, 2020, we entered into a purchase agreement with Lincoln Park, which we refer to in this prospectus as the Purchase Agreement, pursuant to which Lincoln Park agreed to purchase from us up to an aggregate of $15.0 million of our common stock (subject to certain limitations) from time to time over the term of the Purchase Agreement. Through the date of this prospectus, Lincoln Park has purchased an aggregate of approximately $8.0 million of our common stock under the Purchase Agreement. Also on April&#160;22, 2020, we entered into a registration rights agreement with Lincoln Park, which we refer to in this prospectus as the Registration Rights Agreement, pursuant to which we have filed with the SEC the registration statement that includes this prospectus to register for resale under the Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Act, the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock that have been or may be issued to Lincoln Park under the Purchase Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have the right to commence any sales of our common stock to Lincoln Park under the Purchase Agreement until the conditions set forth in the Purchase Agreement, all of which were outside of Lincoln Park&#8217;s control, were satisfied, including that the SEC declared effective a registration statement covering the resale by Lincoln Park of the shares that have been or may be issued pursuant to the Purchase Agreement, which time we refer to in this prospectus as the Commencement. The Commencement occurred on May 19, 2020. On or after the date of the Commencement, we had the right, which we exercised, to direct Lincoln Park to purchase $500,000 in shares of our common stock, which we refer to in this prospectus as the &#8220;Commencement Purchase.&#8221; Thereafter, from time to time, at our sole discretion, we may direct Lincoln Park to purchase shares of our common stock in amounts up to 200,000 shares on any single business day, which amounts may be increased to up to 300,000 shares depending on the market price of our common stock at the time we initiate the sale and subject to a maximum commitment by Lincoln Park of $1.0 million per single purchase, which we refer to in this prospectus as &#8220;Regular Purchases,&#8221; plus other &#8220;accelerated amounts&#8221; and&#47;or &#8220;additional accelerated amounts&#8221; under certain circumstances.  We will control the timing and amount of any sales of our common stock to Lincoln Park  under the Purchase Agreement. The purchase price of the shares that were sold to Lincoln Park in the Commencement Purchase and that have been sold and may be sold in any Regular Purchase was and will be the lower of (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the lowest sale price of our common stock on the business day on which we initiate the purchase and (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the average of the three lowest closing sale prices of our common stock during the 10 consecutive business day period immediately preceding the business day on which we initiate the purchase. The purchase price per share will be equitably adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the business days used to compute such price. We may terminate the Purchase Agreement at any time after the date of Commencement, at no penalty or cost, other than the Commitment Shares (as defined below)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There are no restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement or Registration Rights Agreement, other than a prohibition on our issuing, or entering into any agreement to effect the issuance of, shares of our common stock or common stock equivalents involving a transaction that is defined in the Purchase Agreement as &#8220;Variable Rate Transaction.&#8221; Lincoln Park may not assign or transfer its rights and obligations under the Purchase Agreement. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2020, in consideration for its commitment to purchase shares of our common stock under the Purchase Agreement, we issued 285,714 shares of our common stock to Lincoln Park, which we refer to in this prospectus as the &#8220;Commitment Shares.&#8221;  </font></div></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:45.00pt 54.00pt 45.00pt 54.00pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 4, 2021, there were 41,596,253 shares of our common stock outstanding, of which 39,933,706 shares were held by non-affiliates. The 41,596,253 shares of our common stock outstanding as of January 4, 2021 includes 7,214,286 shares issued and&#47;or sold to Lincoln Park under the Purchase Agreement. If all of the 6,380,126 shares offered by Lincoln Park under this prospectus were issued and outstanding, such shares would represent approximately 13.3% of the total number of shares of our common stock outstanding and approximately 13.8% of the total number of outstanding shares held by non-affiliates, in each case as of January 4, 2021.  The Purchase Agreement provides that we may sell up to $15.0 million of our common stock to Lincoln Park. Through the date of this prospectus, we have sold approximately $8.0 million of our common stock to Lincoln Park under the Purchase Agreement. Depending on the price per share at which we sell shares to Lincoln Park under the Purchase Agreement, we may need to sell more shares to Lincoln Park than are offered under this prospectus to receive aggregate gross proceeds equal to the approximately $7.0 million balance of the $15.0 million total commitment of Lincoln Park under the Purchase Agreement, in which case we must first register for resale under the Securities Act additional shares of our common stock. The number of shares ultimately offered for resale by Lincoln Park will depend upon the number of shares we elect to sell to Lincoln Park under the Purchase Agreement. Sales of our common stock to Lincoln Park by us under the Purchase Agreement could result in substantial dilution to our stockholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable rules of The Nasdaq Stock Market, in no event may we issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of our common stock outstanding immediately prior to the execution of the Purchase Agreement (which is 4,941,089 shares based on 24,705,453 shares outstanding immediately prior to the execution of the Purchase Agreement), which limitation we refer to in this prospectus as the &#8220;Exchange Cap,&#8221; unless (i) we obtain stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price per share of all applicable sales of our common stock to Lincoln Park under the Purchase Agreement equals or exceeds $1.0117 (which represents the closing sale price per share of our common stock on April 21, 2020, plus an incremental amount), such that issuances and sales of our common stock to Lincoln Park under the Purchase Agreement would not be subject to the Exchange Cap under applicable Nasdaq rules. The average price per share of the sales we made to Lincoln Park under the Purchase Agreement through the date of this prospectus was in excess of $1.0117. In any event, the Purchase Agreement specifically provides that we may not issue or sell any shares of our common stock under the Purchase Agreement if such issuance or sale would breach any applicable Nasdaq rules.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase Agreement also prohibits us from directing Lincoln Park to purchase any shares of common stock if those shares, when aggregated with all other shares of our common stock then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership, at any single point in time, of more than 9.99% of the then total outstanding shares of our common stock, as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and Rule 13d-3 thereunder, which limitation we refer to as the Beneficial Ownership Cap.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of shares of our common stock to Lincoln Park will not affect the rights or privileges of our other stockholders, except that the economic and voting interests of each of our other stockholders will be diluted as a result of any such sale. Although the number of shares of common stock that our other stockholders own will not decrease, the shares owned by our other stockholders will represent a smaller percentage of our total outstanding shares after any such sale to Lincoln Park.</font></div></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">9</font></div></div></div><div id="ib7f856a4ed56410bb70efd9cb345751c_13"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:138%">RISK FACTORS</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our securities involves significant risk. In addition to the other information included or incorporated by reference in this prospectus, including the risks, uncertainties and assumptions discussed under the heading &#8220;Risk Factors&#8221; included in our most recent annual report on Form 10-K, as revised or supplemented by our subsequent quarterly reports on Form 10-Q or our current reports on Form 8-K that we have filed with the SEC, all of which are incorporated herein by reference (other than current reports on Form 8-K, or portions thereof, furnished under Items 2.02 or 7.01 of Form 8-K), you should consider the risks described below before making an investment decision with respect to the shares of our common stock in this offering. We expect to update these risk factors and our other risk factors from time to time in periodic and current reports we file with the SEC in the future. Such updated risk factors will be incorporated by reference in this prospectus. Please refer to our subsequently filed reports for additional information relating to the risks associated with investing in our common stock. The risks and uncertainties described in our risk factors are not the only ones we face.  Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. The occurrence of any of these risks might cause you to lose all or part of your investment.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to this Offering</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The sale of our common stock to Lincoln Park may cause dilution to our other stockholders and the subsequent sale of the shares of common stock acquired by Lincoln Park, or the perception that such sales may occur, could cause the price of our common stock to fall.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lincoln Park committed to purchase up to $15.0 million of our common stock under the Purchase Agreement. Through the date of this prospectus, we have sold approximately $8.0 million of our common stock to Lincoln Park under the Purchase Agreement, leaving an approximately $7.0 million balance of the $15.0 million total commitment of Lincoln Park under the Purchase Agreement. The purchase price for the shares that we may sell to Lincoln Park under the Purchase Agreement remains subject to the pricing formula in the Purchase Agreement and will vary based on the price of our common stock at the time we initiate the sale. Depending on market liquidity at the time, sales of such shares may cause the trading price of our common stock to fall.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally have the right to control the timing and amount of any future sales of our shares to Lincoln Park under the Purchase Agreement. Sales of shares of our common stock to Lincoln Park under the Purchase Agreement, if any, will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to Lincoln Park all, some or none of the shares of our common stock that may be available for us to sell pursuant to the Purchase Agreement.  If and when we do sell shares to Lincoln Park, after Lincoln Park has acquired the shares, Lincoln Park may resell all, some or none of those shares at any time or from time to time in its discretion. Therefore, sales to Lincoln Park by us could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our common stock to Lincoln Park, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There may be future sales or other dilution of our equity, which may adversely affect the market price of our common stock, even if our business is doing well.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are generally not restricted from issuing additional common stock, including any securities that are convertible into or exchangeable for, or that represent the right to receive, common stock. To raise additional capital, we may in the future sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that are lower than the prices paid by existing stockholders, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders, which could result in substantial dilution to the interests of existing stockholders. The market price of our common stock could decline as a result of sales of common stock or securities that are convertible into or exchangeable for, or that represent the right to receive, common stock or the perception that such sales could occur.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, we entered into a common stock sales agreement with H.C. Wainwright &#38; Co., LLC, in connection with an &#8220;at the market&#8221; offering, under which, from time to time, we may offer and sell shares of our common stock. We call that sales agreement our &#8220;ATM sales agreement.&#8221; To the extent we sell shares of our common stock under the ATM sales agreement, such sales may result in substantial dilution to our existing stockholders, and such sales, or the anticipation of such sales, may cause the trading price of our common stock to decline.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January&#160;4, 2021, we had outstanding options to purchase up to approximately 2.8 million shares of our common stock and outstanding warrants to purchase up to approximately 1.9 million shares of our common stock. The exercise of a significant portion of our outstanding options and&#47;or warrants may result in significant dilution to our stockholders. In addition, assuming the registration statements under which the shares issuable upon exercise of such options and warrants remain effective, after issuance by us the underlying shares can be freely sold in the public market, except to the extent any such shares are held by an affiliate of ours, in which case such shares will become eligible for sale in the public market as permitted by Rule 144 under the Securities Act or another applicable exemption from registration. The exercise of a significant portion of our outstanding options and&#47;or warrants may result in significant dilution to our stockholders.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under our Agreement and Plan of Merger with Microchips Biotech, Inc., we agreed to pay contingent consideration to the former stockholders of Microchips upon achievement of specified milestones, up to $2.3 million of which we may elect to pay in shares of our common stock, subject to subject to approval of our stockholders to the extent necessary to comply with Nasdaq Listing Rule 5635.  A decision by us to pay contingent consideration that becomes payable to the former stockholders of Microchips in shares of our common stock may result in dilution to our existing stockholders. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding warrants to purchase up to approximately 1.9 million shares of our common stock contain anti-dilution provisions that may be triggered by future sales of our common stock, including to Lincoln Park under the Purchase Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding warrants to purchase up to approximately 1.9 million shares of our common stock include price-based anti-dilution provisions. As of January&#160;4, 2021, the exercise price of those warrants was $0.96 per share. Under the terms of those warrants, subject to certain limited exceptions, their exercise price will be reduced each time we issue or sell any securities, including to Lincoln Park under the Purchase Agreement and under the ATM sales agreement, for a consideration per share less than a price equal to the exercise price of those warrants in effect immediately prior to such issuance or sale. If we issue shares of our common stock for cash, the consideration received therefor will be deemed to be the net amount of consideration we received therefor. Investors in this offering and our other stockholders may be diluted to the extent those warrants are exercised, and the exercise of those warrants or the sale of a significant number of shares issued upon such exercise in the public markets, or the perception that such exercise and&#47;or sales could occur, could adversely affect the price of our common stock. </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require additional financing to sustain our operations and without it we may not be able to execute our current operating plan or continue operations.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred a loss of approximately $19.0 million for the nine months ended September&#160;30, 2020. As of September&#160;30, 2020, we had an accumulated deficit of approximately $63.0 million and cash and cash equivalents of approximately $5.4 million. We also had negative cash flow from operations of approximately $16.0 million during the nine months ended September&#160;30, 2020. We have a history of losses from operations, we expect negative cash flows from our operations to continue for the foreseeable future, and we expect that our net losses will continue for at least the next several years as we develop our existing product candidates and seek to acquire, license or develop additional product candidates. Based on our current operating plan estimates and cash resources, not taking into account any future sales of our shares to Lincoln Park under the Purchase Agreement, we do not believe our existing resources will be sufficient to satisfy our working capital needs and other liquidity requirements over at least the next 12 months. For the foreseeable future, our ability to continue our operations will depend upon our ability to obtain additional capital. These circumstances raise substantial doubt about our ability to continue as a going concern. The Report of Independent Registered Public Accounting Firm included in our annual report on Form 10-K for the year ended December 31, 2019 includes an explanatory statement that our recurring losses from operations, negative cash flow from operations and dependence on additional financing to fund operations raise substantial doubt about our ability to continue as a going concern. We will need to raise substantial additional capital to continue to fund our operations and to successfully execute our current operating plan, including the development of our current product candidates.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may direct Lincoln Park to purchase up to $15.0 million  worth of shares of our common stock under the Purchase Agreement over a 36-month period that began on May 19, 2020, generally in amounts up to 200,000 shares of our common stock on any business day, which amount may be increased to up to 300,000 shares of our common stock depending on the market price of our common stock at the time we initiate the sale and subject to a maximum limit of $1.0 million in any single Regular Purchase. Through the date of this prospectus, we have directed Lincoln Park to purchase approximately $8.0 million worth of shares of our common stock under the Purchase Agreement, leaving an approximately $7.0 million balance of the $15.0 million total commitment of Lincoln Park under the Purchase Agreement.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent we rely on Lincoln Park as a source of funding will depend on a number of factors including, the market price of our common stock over the remaining portion of the 36-month period during which we may sell shares to Lincoln Park under the Purchase Agreement described above, and the extent to which we are able to secure funding from other sources. If obtaining sufficient funding from Lincoln Park were to prove unavailable or prohibitively dilutive, we will need to secure another source of funding in order to satisfy our working capital needs. Even if we were to receive all of the approximately $7.0 million in gross proceeds remaining under the Purchase Agreement, we will still need additional capital to fully implement our business, operating and development plans. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, we will not be able to continue development of our product candidates or we will be required to delay, scale back or eliminate some or all of our development programs or cease operations, and the consequences could be a material adverse effect on our business, operating results, financial condition and prospects.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our management will have broad discretion over the use of the net proceeds from sales of shares of our common stock to Lincoln Park, you may not agree with how we use the proceeds and the proceeds may not be invested successfully. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management will have broad discretion as to the use of the net proceeds from our sale of shares of common stock to Lincoln Park under the Purchase Agreement, and we could use them for purposes other than those contemplated at the time of commencement of this offering. Accordingly, you will be relying on the judgment of our management with regard to the use of those net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that, pending their use, we may invest those net proceeds in a way that does not yield a favorable, or any, return for us or that loses value. The failure of our management to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flows.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">13</font></div></div></div><div id="ib7f856a4ed56410bb70efd9cb345751c_16"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus and the documents incorporated by reference in this prospectus contain or incorporate by reference forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, are forward-looking statements, including statements regarding our strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management. Forward-looking statements, in some cases, can be identified by terms such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;design,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;could,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;contemplate,&#8221; project,&#8221; &#8220;target,&#8221; &#8220;tend to,&#8221; or the negative version of these words and similar expressions.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed under the heading &#8220;Risk Factors&#8221; contained or incorporated in this prospectus and in any related prospectus supplement or free writing prospectus we may authorize for use in connection with this offering. These factors and the other cautionary statements contained or incorporated in this prospectus should be read as being applicable to all related forward-looking statements whenever they appear in this prospectus. Given these uncertainties, you should not place undue reliance on any forward-looking statement. The following factors are among those that may cause such differences&#58;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Inability to continue as a going concern&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Inability to raise additional capital, under favorable terms or at all, including as a result of the effects of the COVID-19 pandemic&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Inability to successfully attract partners and enter into collaborations relating to the development and&#47;or commercialization of our product candidates on a timely basis or on acceptable terms, or at all&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">A decision by Bayer HealthCare LLC to discontinue its commercial interest in Ovaprene and&#47;or to terminate our license agreement&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Inability or an increase in projected costs to timely develop, obtain regulatory approval for and commercialize our product candidates&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Failure or delay in starting, conducting and completing clinical trials or obtaining FDA or foreign regulatory approval for our product candidates in a timely manner, including as a result of matters beyond our control such as the effects related to geopolitical actions, natural disasters, or public health emergencies or pandemics, such as the COVID-19 pandemic&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">A change in the FDA Center assigned primary oversight responsibility for our combination product candidates&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">A change in regulatory requirements for our product candidates, including the development pathway pursuant to Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or the FDA's 505(b)(2) pathway&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Unsuccessful clinical trial outcomes stemming from clinical trial designs, failure to enroll a sufficient number of patients, higher than anticipated patient dropout rates, failure to meet established clinical endpoints, undesirable side effects and other safety concerns&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Reaching a conclusion regarding the efficacy or safety of a product candidate following full evaluation of complete clinical study data that is materially different from topline study results we may report&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Communication from the FDA or another regulatory authority that it does not accept or agree with our assumptions, estimates, calculations, conclusions or analyses of clinical or nonclinical study data regarding a product candidate, or that it interprets or weighs the importance of study data differently than we have in a manner that negatively impacts the candidate's prospects for regulatory approval in a timely manner, or at all&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Negative publicity concerning the safety and efficacy of our product candidates, or of product candidates being developed by others that share characteristics similar to our candidates&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Inability to demonstrate sufficient efficacy of our product candidates&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Failure to select or capitalize on the most scientifically, clinically or commercially promising or profitable indications or therapeutic areas for our product candidates due to limited financial resources&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Loss of our licensed rights to develop and commercialize a product candidate as a result of the termination of the underlying licensing agreement&#59;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Monetary obligations and other requirements in connection with our exclusive, in-license agreements covering the patents and related intellectual property related to our product candidates, or our merger or asset purchase agreements relating to the acquisition of our product candidates&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Developments by our competitors that make our product candidates less competitive or obsolete&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Dependence on third parties to conduct nonclinical studies and clinical trials of our product candidates&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Dependence on third parties to supply and manufacture clinical trial materials and, if any of our candidates are approved, commercial product, including components of our products as well as the finished product, in accordance with current good manufacturing practices and in the quantities needed&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Cyber-attacks, security breaches or similar events compromising our technology systems or the technology systems of third parties on which we rely&#59; </font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Interruptions in, or the complete shutdown of, the operations of third parties on which we rely, including clinical sites, manufacturers, suppliers, and other vendors, from matters beyond their control, such as the effects related to geopolitical actions, natural disasters, or public health emergencies or pandemics, such as the COVID-19 pandemic, and our lack of recourse against such third parties if their inability to perform is excused under the terms of our agreements with such parties&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Failure of our product candidates, if approved, to gain market acceptance or obtain adequate coverage for third party reimbursement&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">A reduction in demand for contraceptives caused by an elimination of current requirements that health insurance plans cover and reimburse certain FDA-cleared or approved contraceptive products without cost sharing&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Uncertainty as to whether health insurance plans will cover our product candidates even if we successfully develop and obtain regulatory approval for them&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Unfavorable or inadequate reimbursement rates for our product candidates set by the United States government and other third-party payers even if they become covered products under health insurance plans&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Difficulty in introducing branded products in a market made up of generic products&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Inability to adequately protect or enforce our, or our licensor&#8217;s, intellectual property rights&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Lack of patent protection for the active ingredients in certain of our product candidates which could expose those product candidates to competition from other formulations using the same active ingredients&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Higher risk of failure associated with product candidates in pre-clinical stages of development that may lead investors to assign them little to no value and make these assets difficult to fund&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Disputes or other developments concerning our intellectual property rights&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Actual and anticipated fluctuations in our quarterly or annual operating results&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Price and volume fluctuations in the stock market, and in our stock in particular, which could subject us to securities class-action litigation&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Failure to maintain the listing of our common stock on the Nasdaq Capital Market or another nationally recognized exchange&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation or public concern about the safety of our potential products&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Strict government regulations on our business, including various fraud and abuse laws, including, without limitation, the U.S. federal Anti-Kickback Statute, the U.S. federal False Claims Act and the U.S. Foreign Corrupt Practices Act&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Regulations governing the production or marketing of our product candidates&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Loss of, or inability to attract, key personnel&#59; and</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Increased costs as a result of operating as a public company, and substantial time devoted by our management to compliance initiatives and corporate governance practices.</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this prospectus or the date of the document incorporated by reference in this prospectus.  We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any statement is made or to reflect the occurrence of unanticipated events, except as required by law.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">15</font></div></div></div><div id="ib7f856a4ed56410bb70efd9cb345751c_19"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:138%">OUR AGREEMENTS WITH LINCOLN PARK</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;22, 2020, we entered into the Purchase Agreement and the Registration Rights Agreement with Lincoln Park. Pursuant to the terms of the Purchase Agreement, Lincoln Park agreed to purchase from us up to $15.0 million of our common stock (subject to certain limitations) from time to time during the term of the Purchase Agreement. Pursuant to the terms of the Registration Rights Agreement, we filed with the SEC the registration statement that includes this prospectus to register for resale under the Securities Act shares that have been or may be issued to Lincoln Park under the Purchase Agreement. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have the right to commence any sales of our common stock to Lincoln Park under the Purchase Agreement until the Commencement occurred, which is the time at which all of the conditions set forth in the Purchase Agreement, all of which were outside of Lincoln Park&#8217;s control, were satisfied, including that the SEC declared effective a registration statement covering the resale by Lincoln Park of the shares that have been or may be issued pursuant to the Purchase Agreement. The Commencement occurred on May 19, 2020. On or after the date of the Commencement, we had the right, which we exercised, to direct Lincoln Park to purchase $500,000 in shares of our common stock. After the Commencement Purchase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from time to time, at our sole discretion, we had the right to direct and may continue to direct Lincoln Park to purchase shares of our common stock in amounts up to 200,000 shares on any single business day as a Regular Purchase. The amount of a Regular Purchase may be increased to up to 300,000 shares depending on the market price of our common stock at the time we initiate the sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subject to a maximum commitment by Lincoln Park of $1.0 million per single Regular Purchase. In addition, at our discretion, Lincoln Park committed to purchase other &#8220;accelerated amounts&#8221; and&#47;or &#8220;additional accelerated amounts&#8221; under certain circumstances. The purchase price per share of the shares that were sold to Lincoln Park in the Commencement Purchase and that have been sold and may be sold in any Regular Purchase was and will be the lower of (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the lowest sale price of our common stock on the business day on which we initiate the purchase and (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the arithmetic average of the three lowest closing sale prices of our common stock during the 10 consecutive business day period immediately preceding the business day on which we initiate the purchase. The purchase price per share will be equitably adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the business days used to compute such price. Lincoln Park may not assign or transfer its rights and obligations under the Purchase Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable rules of The Nasdaq Stock Market, in no event may we issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of our common stock outstanding immediately prior to the execution of the Purchase Agreement (which is 4,941,089 shares based on 24,705,453 shares outstanding immediately prior to the execution of the Purchase Agreement), unless (i) we obtain stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price per share of all applicable sales of our common stock to Lincoln Park under the Purchase Agreement equals or exceeds $1.0117 (which represents the closing sale price of our common stock on April</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21, 2020, plus an incremental amount), such that issuances and sales of our common stock to Lincoln Park under the Purchase Agreement would not be subject to the Exchange Cap under applicable Nasdaq rules. In any event, the Purchase Agreement specifically provides that we may not issue or sell any shares of our common stock under the Purchase Agreement if such issuance or sale would breach any applicable Nasdaq rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase Agreement also prohibits us from directing Lincoln Park to purchase any shares of common stock if those shares, when aggregated with all other shares of our common stock then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park exceeding the Beneficial Ownership Cap.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2020, the day we entered into the Purchase Agreement, we issued the Commitment Shares to Lincoln Park in consideration for its commitment to purchase shares of our common stock under the Purchase Agreement.  </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase of Shares Under the Purchase Agreement</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, at our sole discretion, we may direct Lincoln Park to purchase shares of our common stock in amounts up to 200,000 shares on any single business day as a Regular Purchase&#59; provided that such share limit increases to 250,000 shares if the closing sale price of our common stock is not below $1.50 per share on the business day on which we initiate the purchase, and to 300,000 shares if the closing sale price of our common stock is not below $3.00 per share on the business day on which we initiate the purchase. We refer to such share amount limitation in this prospectus as the &#8220;Regular Purchase Share Limit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; The Regular Purchase Share Limit is subject to proportionate adjustment in the event of a reorganization, recapitalization, non-cash dividend, stock split or other similar transaction&#59; provided, that if, after giving effect to such full proportionate adjustment, the adjusted Regular Purchase Share Limit would preclude us from requiring Lincoln Park to purchase common stock at an aggregate purchase price equal to or greater than $100,000 in any single Regular Purchase, then the Regular Purchase Share Limit will not be fully adjusted, but rather the Regular Purchase Share Limit for such Regular Purchase shall be adjusted as specified in the Purchase Agreement, such that, after giving effect to such adjustment, the Regular Purchase Share Limit will be equal to (or as close as can be derived from such adjustment without exceeding) $100,000. In any case, Lincoln Park&#8217;s maximum commitment in any single Regular Purchase may not exceed $1.0 million. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price per share for the shares that may be sold to Lincoln Park in any Regular Purchase will be the lower of&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lowest sale price of our common stock on the business day on which we initiate the purchase&#59; or</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the arithmetic average of the three lowest closing sale prices for our common stock during the 10-consecutive-business-day period immediately preceding the business day on which we initiate the purchase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to Regular Purchases described above, on any business day on which we have properly submitted a notice directing Lincoln Park to purchase the then applicable Regular Purchase Share Limit and properly delivered all the shares purchased in all prior purchases under the Purchase Agreement, we may direct Lincoln Park to purchase an additional amount of shares of our common stock, which we refer to as an &#8220;Accelerated Purchase,&#8221; not to exceed the lesser of&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">30% of the aggregate shares of our common stock traded during the Accelerated Purchase Measurement Period (as defined below)&#59; and</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">three times the number of shares we directed Lincoln Park to purchase in the corresponding Regular Purchase notice.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this prospectus, the Accelerated Purchase Measurement Period refers to the period that begins at the official open of trading on the business day immediately following the date on which we initiated the corresponding Regular Purchase and ends on the earliest to occur of (a) the official close of trading on that day, (b) the time on that day that the trading volume for our common stock exceeds 3.3 times the number of shares we specified in the Accelerated Purchase notice, and (c)&#160;such time on that day when any share of our common stock trades at a price less than the minimum price per share threshold we set in the applicable Accelerated Purchase notice. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also direct Lincoln Park, by notice delivered before 1&#58;00 p.m. Eastern time on a business day on which an Accelerated Purchase has been completed and all of the shares to be purchased thereunder (and under the corresponding Regular Purchase) have been properly delivered to Lincoln Park in accordance with the Purchase Agreement prior to such time on such business day, to purchase an additional amount of shares of our common stock, which we refer to as an Additional Accelerated Purchase, of up to the lesser of&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">30% of the aggregate shares of our common stock traded during a certain portion of the normal trading hours on such Accelerated Purchase date as determined in accordance with the Purchase Agreement, which period of time we refer to as the Additional Accelerated Purchase Measurement Period&#59; and</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">three times the number of shares we directed Lincoln Park to purchase in Regular Purchase notice corresponding to the Accelerated Purchase that was completed on such Accelerated Purchase date on which an Additional Accelerated Purchase notice was properly received.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, in our sole discretion, submit multiple Additional Accelerated Purchase notices to Lincoln Park prior to 1&#58;00 p.m. Eastern time, on a single Accelerated Purchase date, provided that all prior Accelerated Purchases and Additional Accelerated Purchases (including those that have occurred earlier on the same day) have been completed and all of the shares to be purchased thereunder (and under the corresponding Regular Purchase) have been properly delivered to Lincoln Park in accordance with the Purchase Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price per share for each Accelerated Purchase and each Additional Accelerated Purchase will be equal to the lower of&#58;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">95% of the volume weighted average price of our common stock during the applicable Accelerated Purchase Measurement Period on the applicable Accelerated Purchase date&#59; and</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the closing sale price of our common stock on the applicable Accelerated Purchase date.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the case of any Regular Purchase, Accelerated Purchase and Additional Accelerated Purchase, the purchase price per share will be equitably adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction occurring during the business days used to compute the such price.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as described above, there are no trading volume requirements or restrictions under the Purchase Agreement, and we will control the timing and amount of any sales of our common stock to Lincoln Park.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Events of Default</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Events of default under the Purchase Agreement include the following&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a lapse in the effectiveness of the registration statement of which this prospectus forms for any reason (including, without limitation, the issuance of a stop order or similar order) or unavailability of such registration statement or this prospectus for the resale by Lincoln Park of the shares of our common stock offered hereby that, in each case, continues for a period of 10 consecutive business days or for more than an aggregate of 30 business days in any 365-day period&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the suspension of our common stock from trading on The Nasdaq Capital Market (or such other nationally recognized market or exchange on which our common stock may be listed or traded) for a period of one business day&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the delisting of our common stock from The Nasdaq Capital Market, unless our common stock is immediately thereafter trading or quoted on the New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market, the NYSE American, the NYSE Arca, the OTC Bulletin Board, or OTCQX or OTCQB operated by the OTC Markets Group, Inc. (or nationally recognized successor to any of the foregoing)&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure for any reason by our transfer agent to issue to Lincoln Park the shares purchased by Lincoln Park under the Purchase Agreement within two business days after the date on which Lincoln Park is entitled to receive such shares&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any breach by us of any of our representations, warranties or covenants or other term or condition in the Purchase Agreement or Registration Rights Agreement if such breach would reasonably be expected to have a material adverse effect (as defined in the Purchase Agreement) and, in the case of a breach of a covenant that is reasonably curable, only if such breach is not cured within five business days&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we become insolvent or we, voluntarily or involuntarily, become the subject of any insolvency or bankruptcy proceeding or any such proceeding is threatened against us, as more fully described in the Purchase Agreement&#59; </font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if at any time we are not eligible to transfer shares of our stock electronically through the Depository Trust Company&#8217;s (DTC) Deposit and Withdrawal at Custodian (DWAC) service, or any similar program hereafter adopted by DTC performing substantially the same function&#59; or </font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if at any time the Exchange Cap is reached (to the extent applicable) and our stockholders have not approved the issuance and sale to Lincoln Park of shares in excess of the Exchange Cap.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lincoln Park does not have the right to terminate the Purchase Agreement upon any of the events of default set forth above. During an event of default, or if any event has occurred which, after notice and&#47;or lapse of time, would reasonably be expected to become an event of default under the Purchase Agreement, all of which are outside of Lincoln Park&#8217;s control, we may not direct Lincoln Park to purchase any shares of our common stock under the Purchase Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term of the Purchase Agreement&#59; Termination Rights</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase Agreement will automatically terminate upon the earlier of (a) the date we sell all $15.0 million in shares of our common stock to Lincoln Park under the Purchase Agreement, and (b) the first day of the month immediately following the 36-month anniversary of the date of the Commencement.  The Purchase Agreement will also automatically terminate upon commencement of a voluntary or involuntary bankruptcy proceeding by or against us, as more fully described in the Purchase Agreement.  Now that the Commencement date occurred, we may also, at any time, for any reason or for no reason, terminate the Purchase Agreement upon one business day prior notice to Lincoln Park</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No Short-Selling or Hedging by Lincoln Park</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lincoln Park agreed that neither it nor any of its affiliates will engage, directly or indirectly, in any short-selling or hedging of our common stock during the term of the Purchase Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prohibitions on Variable Rate Transactions</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no restrictions or limitations on our ability to raise capital from other sources at our sole discretion, except that (subject to certain exceptions) we may not enter into any variable rate transaction, as such term is defined in the Purchase Agreement, including any transaction to effect any issuance of shares of our common stock or common stock equivalents with a floating conversion rate or variable purchase price, until the earlier of (a) the 36-month anniversary of the date of the Purchase Agreement and (b) the termination of the Purchase Agreement&#59; provided, however, that, if we terminate the Purchase Agreement, we may not enter into an equity line or similar transaction for 12 months from the date of such termination.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effect of Performance of the Purchase Agreement on Our Stockholders</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All shares registered in this offering which have been or may be issued or sold by us to Lincoln Park under the Purchase Agreement are expected to be freely tradable. Of the 6,380,126 total shares offered for sale by Lincoln Park under this prospectus 130,126 shares were issued by us to Lincoln Park under the Purchase Agreement on or before the date of this prospectus, and 6,250,000 shares may be sold, at our discretion, by us to Lincoln Park under the Purchase Agreement on or after the date of this prospectus and through May 19, 2023. The sale by Lincoln Park of a significant amount of the shares registered in this offering at any given time could cause the market price of our common stock to decline and to be highly volatile. Sales of our common stock to Lincoln Park, if any, will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to Lincoln Park all, some or none of the shares of our common stock that may be available for us to sell pursuant to the Purchase Agreement.  If and when we do sell shares to Lincoln Park, after Lincoln Park has acquired the shares, Lincoln Park may resell all, some or none of those shares at any time or from time to time in its discretion. Therefore, sales to Lincoln Park by us under the Purchase Agreement may result in substantial dilution to the interests of other holders of our common stock. In addition, if we sell a substantial number of shares to Lincoln Park under the Purchase Agreement, or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangement with Lincoln Park may make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect such sales. However, we have the right to control the timing and amount of any additional sales of our shares to Lincoln Park and the Purchase Agreement may be terminated by us at any time at our discretion without any additional cost to us.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the price per share at which we sell our common stock to Lincoln Park pursuant to the Purchase Agreement, we may need to sell more shares to Lincoln Park than are offered under this prospectus to receive aggregate gross proceeds equal to the approximately $7.0 million balance of the $15.0 million total commitment of Lincoln Park under the Purchase Agreement, which could cause additional substantial dilution to our stockholders. If we choose to sell more shares to Lincoln Park than are offered under this prospectus, we must first register for resale under the Securities Act such additional shares of our common stock. The number of shares ultimately offered for resale by Lincoln Park will depend upon the number of shares we elect to sell to Lincoln Park under the Purchase Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase Agreement prohibits us from issuing or selling to Lincoln Park (a) shares of our common stock in excess of the Exchange Cap (which is 4,941,089 shares, or 19.99% of the 24,705,453 shares of our common stock outstanding immediately prior to the execution of the Purchase Agreement), unless (i) we obtain stockholder approval to issue shares in excess of the Exchange Cap or (ii) the average price per share of all applicable sales of our common stock to Lincoln Park under the Purchase Agreement equals or exceeds $1.0117, such that issuances and sales of our common stock to Lincoln Park under the Purchase Agreement would not be subject to the Exchange Cap under applicable Nasdaq rules, and (b)&#160;any shares of our common stock if those shares, when aggregated with all other shares of our common stock then beneficially owned by Lincoln Park and its affiliates, would exceed the Beneficial Ownership Cap.</font></div><div style="margin-bottom:13pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the date of this prospectus, we have received approximately $8.0 million in aggregate gross proceeds from our sale of shares to Lincoln Park under the Purchase Agreement. The average price per share of all such sales was in excess of $1.0117. The following table sets forth the amount of gross proceeds we may receive from Lincoln Park from our sale of shares of our common stock to Lincoln Park at varying assumed average purchase prices per share on or after the date of this prospectus under the Purchase Agreement that are offered for sale by Lincoln Park under this prospectus&#58;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:490.50pt"><tr><td style="width:1.0pt"></td><td style="width:76.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:16.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:115.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:118.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:126.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:90pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assumed Average Purchase Price Per Share</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares to be Issued if Full Purchase (1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Percentage of Outstanding Shares After Giving Effect to Sales to Lincoln Park (2)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proceeds from the Future Sale of Shares to Lincoln Park Under the Purchase Agreement (3)</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.00</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,250,000</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6,250,000</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.34</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,234,771</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7,014,593</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.00</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,507,297</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7,014,593</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.00</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,338,198</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7,014,593</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.00</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753,648</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7,014,593</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The number in this column takes into account that as of the date of this prospectus the remaining balance of the $15.0 million total commitment of Lincoln Park under the Purchase Agreement is approximately $7.0 million, but does not take into account the Beneficial Ownership Cap.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The numerator is the number of shares set forth in the adjacent column which we would have sold under the Purchase Agreement at the corresponding assumed average purchase price set forth in the adjacent column. The denominator is the sum of (a) 41,596,253 shares outstanding as of January 4, 2021 and (b) the number of shares set forth in the adjacent column which we would have sold under the Purchase Agreement at the corresponding assumed average purchase price set forth in the adjacent column.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Reflects the aggregate gross proceeds we would receive from the sale of the shares indicated in this table to Lincoln Park under the Purchase Agreement on or after the date of this prospectus, based on the corresponding assumed average purchase price per share indicated in this table.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The closing price of our common stock on December&#160;31, 2020.</font></div><div><font><br></font></div><div id="ib7f856a4ed56410bb70efd9cb345751c_22"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:138%">USE OF PROCEEDS</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus relates to shares of our common stock that may be offered and sold from time to time by Lincoln Park. See &#8220;Plan of Distribution&#8221; elsewhere in this prospectus for more information. We will not receive any proceeds from the sale of shares by Lincoln Park in this offering.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may receive up to $15.0 million in aggregate gross proceeds from sales of shares of our common stock we make to Lincoln Park pursuant to the Purchase Agreement. Through the date of this prospectus, we received approximately $8.0 million in aggregate gross proceeds from sales of shares of our common stock we made to Lincoln Park pursuant to the Purchase Agreement, leaving an approximately $7.0 million balance of the $15.0 million total commitment of Lincoln Park under the Purchase Agreement. We may choose to sell fewer than $15.0 million in shares of our common stock, or, due to the Exchange Cap and&#47;or the Beneficial Ownership Cap, we may not be able to sell all $15.0 million in shares of our common stock under the Purchase Agreement, in which case we would raise less than $15.0 million in aggregate gross proceeds under the Purchase Agreement. We did not and will not receive any proceeds from the issuance of the Commitment Shares to Lincoln Park.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will have broad discretion in the use of the net proceeds from any sale of shares of our common stock to Lincoln Park under the Purchase Agreement. We intend to use net proceeds from such sales for working capital and general corporate purposes, which include, but are not limited to, advancing our investigational product portfolio and general and administrative expenses. We have not determined the amount of net proceeds to be used specifically for such purposes. Pending the use of any net proceeds, we expect to invest the net proceeds in interest-bearing, marketable securities. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will bear all of the costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including, without limitation, the registration and filing fees, printing fees, Nasdaq listing fees and fees and expenses of our counsel and our accountants.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">20</font></div></div></div><div id="ib7f856a4ed56410bb70efd9cb345751c_25"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:138%">SELLING STOCKHOLDER</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus relates to the possible resale by the selling stockholder, Lincoln Park, of shares of our common stock that have been or may be issued to Lincoln Park pursuant to the Purchase Agreement. We are filing the registration statement of which this prospectus forms a part pursuant to the provisions of the Registration Rights Agreement, which we entered into with Lincoln Park on April&#160;22, 2020 concurrently with our execution of the Purchase Agreement, in which we agreed to provide certain registration rights with respect to sales by Lincoln Park of the shares of our common stock that have been or may be issued to Lincoln Park under the Purchase Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lincoln Park, as the selling stockholder, may, from time to time, offer and sell pursuant to this prospectus any or all of the shares that we have issued or may issue and sell to Lincoln Park under the Purchase Agreement. The selling stockholder may sell some, all or none of those shares. We do not know how long the selling stockholder will hold the shares before selling them, and we currently have no agreements, arrangements or understandings with the selling stockholder regarding its sale of any of the shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information regarding the selling stockholder and the shares that it may offer and sell from time to time under this prospectus. The table is prepared based on information supplied to us by the selling stockholder and reflects its holdings as of January&#160;4, 2021. Neither Lincoln Park nor any of its affiliates has held a position or office, or had any other material relationship, with us or any of our predecessors or affiliates. Beneficial ownership is determined in accordance with Section 13(d) of the Exchange Act and Rule 13d-3 thereunder.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:172.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:79.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:100.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:6.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:137pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br><br><br><br><br><br><br>Selling Stockholder</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br><br><br><br><br>Shares Beneficially Owned Before this Offering</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br>Percentage of Outstanding Shares Beneficially Owned Before this Offering</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares to be Sold in this Offering Assuming the Company issues the Maximum Number of Shares Under the Purchase Agreement</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br>Percentage of Outstanding Shares Beneficially Owned After this Offering</font></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lincoln Park Capital Fund, LLC (1)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,626 (2)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* (3)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,380,126 (4)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* (5)</font></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Less than 1%</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Josh Scheinfeld and Jonathan Cope, the Managing Members of Lincoln Park Capital, LLC, the manager of Lincoln Park Capital Fund, LLC, are deemed to be beneficial owners of all of the shares of common stock owned by Lincoln Park Capital Fund, LLC. Messrs. Cope and Scheinfeld have shared voting and investment power over the shares being offered under this prospectus. Lincoln Park Capital, LLC is not a licensed broker dealer or an affiliate of a licensed broker dealer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Includes 255,500 shares of our common stock issuable to Lincoln Park upon exercise of outstanding and exercisable warrants to purchase our common stock issued on February 15, 2018, which, as of January&#160;4, 2021, have an exercise price of $0.96 per share and expire on February 15, 2023, which we refer to as the February 2018 Warrants. We have excluded from the number of shares beneficially owned by Lincoln Park prior to the offering all of the shares of common stock that Lincoln Park may be required to purchase on or after the date of this prospectus pursuant to the Purchase Agreement, because the issuance of such shares is solely at our discretion and is subject to certain conditions, the satisfaction of all of which are outside of Lincoln Park&#8217;s control, including the registration statement of which this prospectus is a part becoming and remaining effective. Furthermore, under the terms of the Purchase Agreement, issuances and sales of shares of our common stock to Lincoln Park are subject to certain limitations on the amounts we may sell to Lincoln Park at any time, including the Exchange Cap and the Beneficial Ownership Cap. See the description under the heading &#8220;Our Agreements with Lincoln Park&#8221; for more information about the Purchase Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Calculated by dividing (a) the shares in the adjacent column titled &#8220;Shares Beneficially Owned Before this Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; by (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sum of (i) the 41,596,253 shares of our common stock outstanding as of January&#160;4, 2021 and (ii) the 255,500 shares of our common stock issuable to Lincoln Park upon exercise of the February 2018 Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Although we may at our discretion elect to sell to Lincoln Park up to an aggregate amount of an additional approximately $7.0 million of our common stock under the Purchase Agreement, such shares are not included in determining the percentage of shares beneficially owned before this offering.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Assumes issuance of the maximum 6,250,000 shares that are offered for sale by Lincoln Park under this prospectus that are not outstanding as of the date of this prospectus. The Purchase Agreement provides that we may sell up to $15.0 million in shares of our common stock to Lincoln Park. Through the date of this prospectus we have sold approximately $8.0 million in shares of our common stock to Lincoln Park under the Purchase Agreement. Depending on the price per share at which we sell our common stock to Lincoln Park on or after the date of this prospectus pursuant to the Purchase Agreement, we may need to sell to Lincoln Park under the Purchase Agreement more shares of our common stock than are offered under this prospectus to receive aggregate gross proceeds equal to the $15.0 million total commitment of Lincoln Park under the Purchase Agreement. If we choose to do so, we must first register for resale under the Securities Act such additional shares. The number of shares ultimately offered for resale by Lincoln Park will depend upon the number of shares we elect to sell to Lincoln Park under the Purchase Agreement. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Assumes the sale by Lincoln Park of all 6,380,126 shares of our common stock offered for sale by Lincoln Park under this prospectus, although Lincoln Park is under no obligation to sell any shares of common stock at this time. Calculated by dividing (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the 255,500 shares of our common stock issuable to Lincoln Park upon exercise of the February 2018 Warrants, by (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sum of (i) the 41,596,253 shares of common stock outstanding as of January&#160;4, 2021, which includes 7,214,286 shares issued and&#47;or sold to Lincoln Park under the Purchase Agreement through such date, (ii) the 6,250,000 shares which we may sell to Lincoln Park on or after the date of this prospectus under the Purchase Agreement that Lincoln Park may offer and sell under this prospectus and (iii) the 255,500 shares of our common stock issuable to Lincoln Park upon exercise of the February 2018 Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div id="ib7f856a4ed56410bb70efd9cb345751c_28"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:138%">DILUTION</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sale of shares of our common stock to Lincoln Park under the Purchase Agreement will have a dilutive impact on our stockholders. In addition, the lower our stock price is at the time we elect to sell shares to Lincoln Park under the Purchase Agreement, the more shares we will have to issue to Lincoln Park to achieve the same gross proceeds amount, in which case our existing stockholders would experience greater dilution.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net tangible book value as of September&#160;30, 2020 was approximately $(1,385,888), or $(0.0412) per share of common stock. Net tangible book value per share is determined by dividing our total tangible assets, excluding goodwill and intangible assets, less total liabilities, by the number of shares of our common stock outstanding as of September&#160;30, 2020.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the date of this prospectus, we have sold approximately $8.0 million of our common stock to Lincoln Park under the Purchase Agreement, leaving an approximately $7.0 million balance of the $15.0 million total commitment of Lincoln Park under the Purchase Agreement. Assuming a purchase price of $1.34 per share (which was the closing price of our common stock on December&#160;31, 2020), we would need to sell 5,234,771 shares of common stock to Lincoln Park on or after the date of this prospectus under the Purchase Agreement to exhaust such approximately $7.0 million balance. After giving effect to the sale and issuance of such 5,234,771 shares of common stock to Lincoln Park under the Purchase Agreement at an assumed average sale price of $1.34 per share of common stock, our as adjusted net tangible book value as of September&#160;30, 2020 would have been approximately $5,597,790, or $0.1441 per share. This represents an immediate increase in net tangible book value of $0.1854 per share to existing stockholders.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchasers of our common stock in this offering will experience an immediate dilution of the net tangible book value per share of our common stock. Dilution in net tangible book value per share represents the difference between the amount per share paid by purchasers of common stock in this offering, assuming a purchase price of $1.34 per share of common stock (which was the closing price of our common stock on December&#160;31, 2020), and our as adjusted net tangible book value per share after giving effect to this offering.</font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:521.25pt"><tr><td style="width:1.0pt"></td><td style="width:361.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed offering price per share of common stock</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.34&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:11.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net tangible book value per share as of September&#160;30, 2020</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.0412)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in net tangible book value per share attributable to this offering</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1854&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As adjusted net tangible book value per share after giving effect to this offering</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1441&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilution per share to new investors</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1959&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of our common stock to be outstanding as shown above is based on 33,602,516 shares outstanding as of September&#160;30, 2020, and excludes&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%;padding-left:14.5pt">1,908,643 shares of common stock issuable upon exercise of warrants outstanding as of September&#160;30, 2020, having a weighted average exercise price of $1.41 per share&#59;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%;padding-left:14.5pt">2,783,591 shares of common stock issuable upon exercise of stock options outstanding as of September&#160;30, 2020, having a weighted average exercise price of $1.16 per share&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%;padding-left:14.5pt">507,516 shares of common stock reserved for future issuance under our Amended and Restated 2014 Stock Incentive Plan as of September&#160;30, 2020&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%;padding-left:14.5pt">4,661,611 shares of common stock issued after September&#160;30, 2020 pursuant to our &#34;at the market&#34; offering program&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%;padding-left:14.5pt">3,332,126 shares of common stock we sold to Lincoln Park under the Purchase Agreement after September&#160;30, 2020 and through the date of this prospectus.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that outstanding options or warrants have been or may be exercised, the exercise price of the February 2018 Warrants is adjusted downward in accordance with the price-based anti-dilution provisions of such warrants, new equity awards were are or issued, shares of our common stock are sold under our employee stock purchase plan, or we otherwise issued or issue additional shares of common stock, including to Lincoln Park under the Purchase Agreement and in our &#8220;at the market&#8221; offering program through H.C. Wainwright &#38; Co., LLC, investors purchasing our common stock in this offering may experience further dilution.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">23</font></div></div></div><div id="ib7f856a4ed56410bb70efd9cb345751c_31"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:138%">PLAN OF DISTRIBUTION</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common stock offered by this prospectus is being offered by the selling stockholder, Lincoln Park. The common stock may be sold or distributed from time to time by the selling stockholder directly to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. The sale of the common stock offered by this prospectus could be effected in one or more of the following methods&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%;padding-left:14.5pt">ordinary brokers&#8217; transactions&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%;padding-left:14.5pt">transactions involving cross or block trades&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%;padding-left:14.5pt">through brokers, dealers, or underwriters who may act solely as agents&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%;padding-left:14.5pt">&#8220;at the market&#8221; into an existing market for the common stock&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%;padding-left:14.5pt">in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected through agents&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%;padding-left:14.5pt">in privately negotiated transactions&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%;padding-left:14.5pt">any combination of the foregoing.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to comply with the securities laws of certain states, if applicable, the shares may be sold only through registered or licensed brokers or dealers. In addition, in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from the state&#8217;s registration or qualification requirement is available and complied with.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lincoln Park is an &#8220;underwriter&#8221; within the meaning of Section 2(a)(11) of the Securities Act.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lincoln Park has informed us that it intends to use an unaffiliated broker-dealer to effectuate all sales, if any, of the common stock that it may purchase from us pursuant to the Purchase Agreement. Such sales will be made at prices and at terms then prevailing or at prices related to the then current market price. Each such unaffiliated broker-dealer will be an underwriter within the meaning of Section 2(a)(11) of the Securities Act. Lincoln Park has informed us that each such broker-dealer will receive commissions from Lincoln Park that will not exceed customary brokerage commissions.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brokers, dealers, underwriters or agents participating in the distribution of the shares as agents may receive compensation in the form of commissions, discounts, or concessions from the selling stockholder and&#47;or purchasers of the common stock for whom the broker-dealers may act as agent. The compensation paid to a particular broker-dealer may be less than or in excess of customary commissions. Neither we nor Lincoln Park can presently estimate the amount of compensation that any agent will receive.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We know of no existing arrangements between Lincoln Park or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the shares offered by this prospectus. At the time a particular offer of shares is made, a prospectus supplement, if required, will be distributed that will set forth the names of any agents, underwriters or dealers and any compensation from the selling stockholder, and any other required information.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay the expenses incident to the registration, offering, and sale of the shares to Lincoln Park. We have agreed to indemnify Lincoln Park and certain other persons against certain liabilities in connection with the offering of shares of common stock offered hereby, including liabilities arising under the Securities Act or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Lincoln Park has agreed to indemnify us against liabilities under the Securities Act that may arise from certain written information furnished to us by Lincoln Park specifically for use in this prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lincoln Park has represented to us that at no time prior to the Purchase Agreement has Lincoln Park or its agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of our common stock or any hedging transaction, which establishes a net short position with respect to our common stock. Lincoln Park agreed that during the term of the Purchase Agreement, it, its agents, representatives or affiliates will not enter into or effect, directly or indirectly, any of the foregoing transactions.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have advised Lincoln Park that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M precludes the selling stockholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered by this prospectus.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This offering will terminate on the earlier of (i) termination of the Purchase Agreement or (ii) the date that all shares offered by this prospectus have been sold by Lincoln Park.</font></div><div id="ib7f856a4ed56410bb70efd9cb345751c_541"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE AND DIRECTOR COMPENSATION</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Compensation</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation committee of our board of directors assists our board in discharging its responsibilities in respect of compensation of our executive officers. The compensation committee is currently comprised of three non-employee members of our board, Cheryl R. Blanchard, Ph.D., William H. Rastetter, Ph.D. and Robin J. Steele, J.D., L.L.M.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive compensation is intended to attract and retain qualified executive officers and to align the interests of our executive officers with those of our stockholders by incentivizing and rewarding achievement of business objectives that we believe will enhance our value and by promoting commitment to long-term success. As a clinical-stage biopharmaceutical company, these objectives are to be accomplished primarily by positioning us to successfully execute our drug product development and regulatory approval efforts and to translate those efforts, over time, into revenues and income from commercialization of, or strategic collaborations with respect to, our product candidates.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current executive compensation program primarily includes (1)&#160;base salary, (2)&#160;annual performance-based incentive compensation, and (3)&#160;long-term incentive compensation in the form of stock options with the goal of aligning the long-term interests of executive officers with those of our stockholders and otherwise encouraging the achievement of superior results over an extended time period.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the compensation of our Chief Executive Officer, the compensation committee annually reviews and recommends to our board corporate objectives relevant to compensation, evaluates performance in light of those objectives, and recommends to our board compensation levels based on this evaluation. Our Chief Executive Officer may not be present during any deliberations or voting with respect to her compensation. The compensation committee annually reviews and approves the compensation of our other executive officers.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our executive officer compensation program, the compensation committee also&#58; (1)&#160;reviews competitive practices and trends to determine the adequacy of our executive compensation program&#59; (2)&#160;reviews and considers participation and eligibility in the various components of our total executive compensation package&#59; and (3)&#160;as deemed necessary or appropriate, approves employment contracts, severance arrangements, change in control provisions and other agreements.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a formal policy for the timing of granting annual equity awards to our existing employees, including our named executive officers, to provide for a consistent process and to ensure the integrity and efficiency of the company&#8217;s award process. Under this policy, annual equity awards will be granted on the date of the compensation committee&#8217;s first regularly scheduled meeting held each year, subject to the compensation committee&#8217;s ability to change the annual grant date for any particular year if the compensation committee determines that granting annual awards on such date would not be in the company&#8217;s best interest.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the compensation awarded to or paid to, or earned by our named executive officers for the years ended December&#160;31, 2020 and 2019. Mr. Fair was not a named executive officer for the year ended December 31, 2019, and therefore information in the table below is provided only with respect to his compensation for the year ended December&#160;31, 2020.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"></td><td style="width:130.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:30.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:18pt"><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Summary&#160;Compensation&#160;Table</font></td></tr><tr style="height:47pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name&#160;and&#160;Principal&#160;Position</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal<br>Year</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salary<br>($)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bonus<br>($)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option<br>Awards ($) (1)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-equity incentive plan compensation<br>($) (2)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">All&#160;Other<br>Compensation ($) (3)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br>($)</font></td></tr><tr style="height:26pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sabrina Martucci Johnson</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,225&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,845&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,241&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,311&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,750&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,534&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,269&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,200&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628,753&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisa Walters-Hoffert</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,580&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,262&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,952&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,794&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,800&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,051&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,671&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,200&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,722&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Fair</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,580&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,262&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,320&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,162&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Strategy Officer</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">The amounts in this column represent the grant date fair value, determined in accordance with ASC Topic 718, Compensation-Stock Compensation (ASC Topic 718), of stock options granted to the applicable individual. With respect to the stock options granted during 2019, see Note 8. Stock-Based Compensation to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 27, 2020 for details as to the assumptions used to determine the fair value of the awards. With respect to the stock options granted during 2020, the following assumptions were used to determine the fair value of the awards&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:36pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:313.50pt"><tr><td style="width:1.0pt"></td><td style="width:246.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</font></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</font></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</font></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of options granted</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Amounts represent performance bonuses earned for the years indicated. As of the date of this prospectus, the bonus earned by our named executive officers for 2020 have not yet been determined. Such bonuses are expected to be determined by the end of March 2021 and will be based on our company's achievement, as determined by the compensation committee and&#47;or our board of directors, of performance objectives. The target bonus amounts for Ms. Johnson, Ms. Walters-Hoffert and Mr. Fair will be up to 50%, 35% and 35%, respectively, of their respective 2020 annual base salary, and the compensation committee will have the sole discretion to apply a weighting of 0 to 150% against the target bonus percentage.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Amount reflects a company 401(k) match. We provide the named executive officers with health, medical and other non-cash benefits generally available to all employees, which are not included in these columns pursuant to SEC rules.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Narrative to Summary Compensation Table</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As reflected in the table above, the 2020 compensation of our named executive officers consisted of three primary components&#58; (1) base salary&#59; (2) equity compensation in the form of stock options&#59; and (3) performance-based cash compensation. As noted in the table above, the amount of the performance-based cash compensation for 2020 has not yet been determined.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The 2020 annual base salary of our named executive officers was $368,225 for Ms. Ms.&#160;Johnson, $294,580 for Ms.&#160;Walters-Hoffert, and $294,580 for Mr. Fair.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Option Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our named executive officers were each granted a stock option during 2020. Stock options are a key tool in our pay-for-performance philosophy and align the interests of our employees, including our named executive officers, with our stockholders&#8217; interests. Stock options are inherently performance-based, and automatically link executive pay to stockholder return, as the value realized, if any, by the recipient from a stock option depends upon, and directly proportionate to, the appreciation in our stock price. In preparation for making 2020 executive officer compensation decisions, the compensation committee evaluated the appropriate form of long-term incentive compensation and determined to use stock options as the primary incentive for long-term compensation in part because of the foregoing reasons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreements and Termination of Employment&#160;&#38; Change in Control Arrangements</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have written agreements with each of Ms.&#160;Johnson, Ms.&#160;Walters-Hoffert and Mr. Fair governing the terms of their employment with us. The following is a summary of the material terms of such agreements, as amended to date, necessary to an understanding of the information disclosed in the summary compensation table. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each executive is eligible to receive an annual base salary, which may be adjusted at the discretion&#160;of&#160;our&#160;board.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our sole discretion, Ms.&#160;Johnson and Ms.&#160;Walters-Hoffert are each eligible to receive an annual bonus in an amount equal to up to 50% and 35%, respectively, of each their respective then-current annual base salary. Under the terms of his agreement, Mr. Fair's annual bonus was initially targeted at 30% of his base salary, which was increased to 35% in 2020. The amount of their annual bonus, if any, will be based on the applicable executive&#8217;s performance and our company&#8217;s performance as measured against performance objectives and determined by the compensation committee and&#47;or our board of directors.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each executive is entitled to (1)&#160;participate in all equity, pension, savings and retirement plans, welfare and insurance plans, practices, policies, programs and perquisites of employment applicable generally to our senior executives, (2)&#160;receive reimbursement for reasonably incurred business expenses and (3)&#160;receive paid vacation and holiday time in accordance with policies generally applicable to our senior executives.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to earlier termination, including in the event of death, the employment agreement with each of Ms. Johnson and Ms. Walters-Hoffert is for a two-year term and automatically renews for successive one-year terms unless either party provides notice of her intent not to renew at least 60 days prior to the applicable expiration date. Ms. Johnson and Ms. Walters-Hoffert may terminate her respective employment for good reason after giving us 14 days to correct or &#8220;cure&#8221; the circumstances giving rise to a termination for good reason, or for any reason other than for good reason a upon at least 14 days&#8217; prior written notice. We may terminate the employment of Ms. Johnson and Ms. Walters-Hoffert without prior written notice for cause, without cause on 14 days&#8217; prior written notice, or in the event of the executive&#8217;s disability. Their employment agreement automatically terminates upon the executive&#8217;s death. Our agreement with Mr. Fair is &#34;at will,&#34; meaning that either he or we may terminate his employment at any time and for any reason, with or without cause.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our obligations and the payments and other benefits to which Ms. Johnson and Ms. Walters-Hoffert may be entitled if her employment is terminated for the reason specified, other than in connection with a change of control, which is discussed in the paragraph below the table.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.138%"><tr><td style="width:1.0%"></td><td style="width:21.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.520%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reason&#160;for<br>Termination</font></td><td colspan="3" style="background-color:#acacac;padding:0 1pt"></td><td colspan="3" style="background-color:#acacac;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#acacac;padding:0 1pt"></td><td colspan="3" style="background-color:#acacac;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash&#160;Payments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="background-color:#acacac;padding:0 1pt"></td><td colspan="3" style="background-color:#acacac;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other&#160;Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By us for cause.<br>By the executive without good reason.<br>Executive&#8217;s death or disability.<br>Executive elects not to renew agreement.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We must pay the executive&#160;any accrued obligations as of the date of termination</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By us other than for cause.<br>By the executive with good reason.<br>We elect not to renew agreement.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We must pay the executive any accrued obligations as of the date of termination</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We must pay the executive&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> any accrued but unpaid bonus (or a pro rata portion of such bonus) as of the date of termination&#59; and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> an amount equal to a specified number of months of the executive&#8217;s then-current base salary.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We must provide the executive continuing health benefits coverage for a specified number of months.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Consists of any earned but unpaid base salary, unpaid expense reimbursements, and any vested benefits the executive may have under any employee benefit plan, in each case, as of the date of termination.</font></div><div style="margin-bottom:6pt;padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Payment and benefits are conditioned on (a)&#160;the executive&#8217;s continued compliance with her obligations under the employment agreement related to confidentiality and non-interference and intellectual property covenants and (b)&#160;the executive (or her estate) executing and delivering a full release of all claims in favor of Dar&#233;.</font></div><div style="margin-bottom:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">The number of months is 12 for Ms.&#160;Johnson and 9 for Ms.&#160;Walters-Hoffert.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our employment agreements with Ms. Johnson and Ms. Walters-Hoffert, if their respective employment is terminated by us without cause or by the executive for good reason, in each case, within three months prior to or 12 months following a change of control, then, subject to the applicable executive's continued compliance with customary confidentiality, intellectual property assignment and similar obligations to us, and subject to the delivery of a full release of claims in our favor by the executive, (1)&#160;the executive is eligible to receive an amount equal to a specified number of months (18 for Ms.&#160;Johnson and 12 for Ms.&#160;Walters-Hoffert) of the executive&#8217;s then-current base salary and target bonus at the rate in effect immediately prior to such termination, (2)&#160;the executive will receive continuing health benefits coverage for a specified number of months (18 for Ms.&#160;Johnson and 12 for Ms.&#160;Walters-Hoffert) and (3)&#160;any unvested and outstanding equity interests such executive may have in Dar&#233; will fully vest and accelerate.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our change in control policy in which our employees at vice president and above are eligible to participate, if the employment of an employee covered by such policy is terminated by us without cause or if such employee resigns for good reason, in either case, within 90 days before, or 365 days following, the effective date of a change in control, then, subject to the applicable employee's continued compliance with customary confidentiality, intellectual property assignment and similar obligations to us, and subject to the delivery of a full release of claims in our favor by such employee, the vesting of all of such employee's equity awards then outstanding that are subject solely to time-based vesting conditions that have not been satisfied will be accelerated in full. The vesting of any equity award that is subject only to performance-based vesting condition(s) or to both performance-based vesting condition(s) and time-based vesting condition(s), will not be accelerated unless such performance-based vesting condition(s) have been satisfied as of the effective date of the termination of employment or, in the case of a termination that occurs before a change in control, as of the effective date of the change in control. Mr. Fair is covered by our change in control policy, however, neither Ms. Johnson nor Ms. Walters-Hoffert are so covered.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments made and benefits available to each executive in connection with their employment agreement and under our change in control policy will comply with Internal Revenue Code Section&#160;409A in accordance with the terms of such documents.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Benefits</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a defined contribution employee retirement plan for all our employees. Our 401(k) plan is intended to qualify as a tax-qualified plan under Section&#160;401 of the Internal Revenue Code so that contributions to our 401(k) plan, and income earned on such contributions, are not taxable to participants until withdrawn or distributed from the 401(k) plan. If a participant contributes 5% or more of their compensation, we match their contribution up to 4% of their annual compensation, subject to statutory limits.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have any annuity, pension or deferred compensation plan or other arrangements for our executive officers or any employees.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Equity Awards at Fiscal Year-End</font></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning equity awards held by our named executive officers that were outstanding as of December&#160;31, 2020&#58;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:177.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020&#160;Outstanding&#160;Equity&#160;Awards&#160;at&#160;Fiscal&#160;Year-End<br>Option&#160; Awards</font></td></tr><tr style="height:72pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date&#160;of&#160;Grant</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br>Securities<br>Underlying<br>Unexercised<br>Options<br>Exercisable<br>(#)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br>Securities<br>Underlying<br>Unexercised<br>Options<br>Unexercisable<br>(#)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option<br>Exercise<br>Price<br>($)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option<br>Expiration<br>Date</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sabrina Martucci Johnson</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#47;7&#47;2018</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#47;7&#47;2028</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#47;29&#47;2019</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,437&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,563&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.759&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#47;29&#47;2029</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#47;6&#47;2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,500&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,500&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.03&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#47;6&#47;2030</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisa Walters-Hoffert</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#47;7&#47;2018</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,250&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,750&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#47;7&#47;2028</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#47;29&#47;2019</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,937&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,063&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.759&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#47;29&#47;2029</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#47;6&#47;2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,750&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,250&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.03&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#47;6&#47;2030</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Fair</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#47;7&#47;2018</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,375&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,625&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#47;7&#47;2028</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#47;29&#47;2019</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,937&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,063&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.759&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#47;29&#47;2029</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#47;6&#47;2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,750&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,250&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.03&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#47;6&#47;2030</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Compensation</font></div><div style="margin-bottom:7pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the assistance of the compensation committee, our board of directors periodically reviews and evaluates our non-employee director compensation policy. The following is an overview of our non-employee director compensation policy during 2020, which was designed to allow us to recruit and retain individuals with the requisite experience, skills and characteristics for membership on our board of directors, and to align the interests of our directors with those of our stockholders through the grant of stock options.</font></div><div style="margin-bottom:7pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retainers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each of our non-employee directors was paid a retainer for service on our board and for each board committee on which the director served as shown in the table below. Retainers are paid in cash in arrears in four equal quarterly installments, prorated to reflect the actual time served by the director during such quarter. Directors may elect to receive up to 100% of their retainer in the form of awards of unrestricted shares of our common stock. If so elected, on the first trading day of the quarter following the quarter to which the retainer relates, we would issue a number of shares of common stock equal to (x)&#160;the amount of the cash retainer that would otherwise have been payable to such director on the date of grant divided by (y)&#160;the fair market value of our common stock on the date of grant. Directors wishing to make this election for a given calendar year must make the election on or before the last day of the prior calendar year, except that the election with respect to any year in which a director is newly elected must be made on or before June 30th of such year or such other date as determined by our board.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:412.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Annual&#160;Retainer&#160;($)</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Board of Directors</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Board Committees</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit Chair</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit Member</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation Chair</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation Member</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nominating and Corporate Governance Chair</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nominating and Corporate Governance Member</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Awards</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each director newly elected to our board receives an option to purchase 45,000 shares of our common stock, which vests as to 15,000 shares on each anniversary of the grant date until the third anniversary of the grant date, subject to the director&#8217;s continued service as a director, and will become exercisable in full upon a change in control. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  On the date of each annual meeting of stockholders, each director that has served on our board for at least six months (and, if up for election at such annual meeting, is elected at such annual meeting) receives an option to purchase 22,500 shares of our common stock, which will vest in full on the earlier of the first anniversary of the grant date or immediately prior to our first annual meeting of stockholders occurring after the grant date, subject to the director&#8217;s continued service as a director, and will become exercisable in full upon a change in control.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of each option granted under our non-employee director compensation policy is set at the fair market value of our common stock on the grant date.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expense Reimbursement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We reimburse our non-employee directors for reasonable travel and other expenses incurred in connection with attending board and committee meetings.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Director Compensation</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the compensation of our non-employee directors during 2020.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:495.75pt"><tr><td style="width:1.0pt"></td><td style="width:163.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:90.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:69.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:75.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:20pt"><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020&#160;Director&#160;Compensation</font></td></tr><tr style="height:23pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fee&#160;Earned&#160;or<br>Paid&#160;in&#160;Cash</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option<br>Awards&#160;(1)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All&#160;Other<br>Compensation</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cheryl R. Blanchard, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,629&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,806&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,435&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jessica D. Grossman, M.D.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,806&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,806&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Susan L. Kelley, M.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,806&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,806&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory W. Matz, CPA</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,806&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,806&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William H. Rastetter, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,806&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,806&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robin J. Steele</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,500&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,806&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,306&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">The amounts in this column represent the grant date fair value, determined in accordance with ASC Topic 718, Compensation-Stock Compensation (ASC Topic 718), of stock options granted to the applicable individual. See Footnote 1 to the 2020 Summary Compensation Table for our named executive officers under the section entitled &#34;&#8212;Executive Compensation,&#34; above, for the assumptions used to determine the fair value of these awards.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our non-employee directors had stock options outstanding to purchase the following number of shares of our common stock&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:487.50pt"><tr><td style="width:1.0pt"></td><td style="width:385.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">#&#160;of&#160;Shares&#160;Subject&#160;to<br>Outstanding&#160;Options</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cheryl R. Blanchard, Ph.D.</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,500&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jessica D. Grossman, M.D.</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Susan L. Kelley, M.D.</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,300&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory W. Matz, CPA</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William H. Rastetter, Ph.D.</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,301&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robin Steele, J.D.,L.L.M.</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,200&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div id="ib7f856a4ed56410bb70efd9cb345751c_34"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:138%">LEGAL MATTERS</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breakwater Law Group, LLP, Solana Beach, California, will pass upon the validity of the common stock being offered by this prospectus.</font></div><div id="ib7f856a4ed56410bb70efd9cb345751c_37"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:138%">EXPERTS</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mayer Hoffman McCann P.C., an independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019, as set forth in its report, which is incorporated by reference in this prospectus and the registration statement.  Our financial statements are incorporated by reference in reliance on Mayer Hoffman McCann P.C.&#8217;s report, given on the authority of said firm as experts in accounting and auditing.</font></div><div id="ib7f856a4ed56410bb70efd9cb345751c_40"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:138%">WHERE YOU CAN FIND MORE INFORMATION</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers, such as our company, that file documents electronically with the SEC. Our SEC filings are available to the public at the SEC&#8217;s website address at http&#58;&#47;&#47;www.sec.gov. The&#160;information on the SEC&#8217;s website is not part of this prospectus, and any references to the SEC&#8217;s website or any other website are inactive textual references only. We also maintain a website at www.darebioscience.com, through which you can access our SEC filings.  The information set forth on our website is not part of this prospectus.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus is only part of a registration statement on Form S-1 that we have filed with the SEC. This prospectus omits some information contained in the registration statement in accordance with SEC rules and regulations.  You should review the information in and schedules and&#47;or exhibits to the registration statement for further information about us and the securities being offered pursuant to this prospectus. Statements in this prospectus concerning any document we filed as an exhibit or schedule to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate these statements. </font></div><div id="ib7f856a4ed56410bb70efd9cb345751c_43"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:138%">INCORPORATION OF DOCUMENTS BY REFERENCE</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC allows us to &#8220;incorporate by reference&#8221; into this prospectus much of the information that we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference into this prospectus is an important part of this prospectus. This prospectus incorporates by reference the documents listed below and any future filings we make with the SEC pursuant to Sections 13(a), 13,(c), 14 or 15(d) of the Exchange Act after the effective date of the registration statement of which this prospectus is a part and prior to the termination or completion of this offering, other than information furnished to, rather than filed with the SEC&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%;padding-left:14.5pt">our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 27, 2020  (the &#8220;Annual Report&#8221;), including all material incorporated by reference therein, which includes the portions of our definitive proxy statement on Schedule 14A filed with the SEC on April 22, 2020 incorporated by reference into Part III of the Annual Report&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%;padding-left:14.5pt">our Quarterly Reports on Form 10-Q for each of the three months ended March 31, 2020, June 30, 2020 and September 30, 2020, filed with the SEC on May 14, 2020, August 12, 2020 and November 12, 2020, respectively&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%;padding-left:14.46pt">our Current Reports on Form 8-K and on Form 8-K&#47;A filed with the SEC on January 9, 2020, January 13, 2020, January 30, 2020, February 5, 2020, February 6, 2020, February 10, 2020, March 16, 2020, April 23, 2020, April 27, 2020, June 3, 2020, June 8, 2020, June 26, 2020, September 9, 2020, October 6, 2020, November 18, 2020, December 7, 2020 and December 9, 2020 (except for the information furnished under Items 2.02 or 7.01 and the exhibits furnished thereto)&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%;padding-left:14.5pt">the description of our common stock contained in our Registration Statement on Form 8-A filed on April 4, 2014, including any amendments thereto or reports filed for the purpose of updating such description, including the description of our common stock in Exhibit 4.6 of the Annual Report. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC file number for each of the documents listed above is 001-36395.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the statement.  Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will provide to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request and at no cost to the requester, a copy of any or all reports or documents that are incorporated by reference into this prospectus, but not delivered with the prospectus. Such written or oral requests should be directed to&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dar&#233; Bioscience, Inc. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3655 Nobel Drive, Suite 260 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, CA 92122</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attn&#58; Chief Financial Officer</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Telephone&#58;  (858) 926-7655</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You may also access these incorporated reports and other documents on our website, www.darebioscience.com.  The information contained on, or that can be accessed through, our website is not a part of this prospectus.  We have included our website address in this prospectus solely as an inactive textual reference.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should rely only on information contained in, or incorporated by reference into, this prospectus and any related prospectus supplement.  We have not authorized anyone to provide you with information different from that contained in this prospectus or incorporated by reference in this prospectus.  We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center"><img alt="darebioinlinefullcolorrgbaa.jpg" src="darebioinlinefullcolorrgbaa.jpg" style="height:108px;margin-bottom:5pt;vertical-align:text-bottom;width:269px"></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6,380,126 Shares of Common Stock</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">PROSPECTUS</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January&#160;7, 2021</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">33</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>darebioinlinefullcolorrgbaa.jpg
<TEXT>
begin 644 darebioinlinefullcolorrgbaa.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D="                  #VU@ !     -,M2% @(
M                                            $6-P<G0   %0
M,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M    %&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0
M  +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE
M87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (
M#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE
M='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V
M+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                  !865H@
M    \U$  0    $6S%A96B                      6%E:(        &^B
M   X]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0
M +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M   6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                 &1E<V,         +DE%0R V,3DV
M-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M    +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@
M<U)'0@                            !D97-C         "Q2969E<F5N
M8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0                                  =FEE=P      $Z3^ !1?+@ 0
MSQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M      $                        "CP    )S:6<@     $-25"!C=7)V
M        !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0
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MBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____N  Y!9&]B90!DP
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M&?_:  P# 0 "$0,1 #\ W\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_?SS7_K7_LUG_LX_VP_(W^T3_P"D=%_ZL#^[_2/_ ,)_UM;^,']_/-?^M?\
MLUG_ +.7.Z)DKN9T?3<QDIOK.1RNJ:[DK]CVXH?K%V]B*=JU-[->.*"+W9Y7
M.[6-:QO7HB(G1"O&9T:=OF5Q;T5A1IUZD8K:\%&;26+Q;P2Z7B7_ --7=QF&
MG,OO[N7'=U[*A4G+!+BG.E&4GA%)+%MO!))="2/5GPGM@
M
M
M
M                                           BIYQ?A+YV^X]K]=HD
M3<]?LBS_ .02]*)-GAQ^W+37TE'T)F1HQ^-U   #8IRS^&S<_P"%5O[ :;U:
M ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<RP   -$_&'[M.//N-J7V!CRI>=?/%
MW\IJ^G(U4T=]4,J^C;;X&![D\PZ0
M
M
M
M                          $5/.+\)?.WW'M?KM$B;GK]D6?_ ""7I1)L
M\./VY::^DH^A,R-&/QNH   ;%.6?PV;G_"JW]@--ZM ?.&4>ZM_P1/YEN='U
M3U+\FO/RRALMN98   &B?C#]VG'GW&U+[ QY4O.OGB[^4U?3D:J:.^J&5?1M
MM\# ]R>8=(
M
M
M
M        "*GG%^$OG;[CVOUVB1-SU^R+/_D$O2B39X<?MRTU])1]"9D:,?C=
M0   V*<L_ALW/^%5O[ :;U: ^<,H]U;_ ((G\RW.CZIZE^37GY90V6W,L
M#1/QA^[3CS[C:E]@8\J7G7SQ=_*:OIR-5-'?5#*OHVV^!@>Y/,.D
M
M
M
M                                                  !%3SB_"7SM
M]Q[7Z[1(FYZ_9%G_ ,@EZ42;/#C]N6FOI*/H3,C1C\;J   &Q3EG\-FY_P *
MK?V TWJT!\X91[JW_!$_F6YT?5/4OR:\_+*&RVYE@   :)^,/W:<>?<;4OL#
M'E2\Z^>+OY35].1JIH[ZH95]&VWP,#W)YAT@
M
M
M
M                                  (J><7X2^=ON/:_7:)$W/7[(L_^
M02]*)-GAQ^W+37TE'T)F1HQ^-U   #8IRS^&S<_X56_L!IO5H#YPRCW5O^")
M_,MSH^J>I?DUY^64-EMS+    T3\8?NTX\^XVI?8&/*EYU\\7?RFKZ<C531W
MU0RKZ-MO@8'N3S#I
M
M
M
M               14\XOPE\[?<>U^NT2)N>OV19_\@EZ42;/#C]N6FOI*/H3
M,C1C\;J   &Q3EG\-FY_PJM_8#3>K0'SAE'NK?\ !$_F6YT?5/4OR:\_+*&R
MVYE@   :)^,/W:<>?<;4OL#'E2\Z^>+OY35].1JIH[ZH95]&VWP,#W)YAT@
M
M
M
M                                                         (J>
M<7X2^=ON/:_7:)$W/7[(L_\ D$O2B39X<?MRTU])1]"9D:,?C=0   V*<L_A
MLW/^%5O[ :;U: ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<RP   -$_&'[M.//N
M-J7V!CRI>=?/%W\IJ^G(U4T=]4,J^C;;X&![D\PZ0
M
M
M
M                                       $5/.+\)?.WW'M?KM$B;GK
M]D6?_()>E$FSPX_;EIKZ2CZ$S(T8_&Z@  !L4Y9_#9N?\*K?V TWJT!\X91[
MJW_!$_F6YT?5/4OR:\_+*&RVYE@   :)^,/W:<>?<;4OL#'E2\Z^>+OY35].
M1JIH[ZH95]&VWP,#W)YAT@
M
M
M
M                    (J><7X2^=ON/:_7:)$W/7[(L_P#D$O2B39X<?MRT
MU])1]"9D:,?C=0   V*<L_ALW/\ A5;^P&F]6@/G#*/=6_X(G\RW.CZIZE^3
M7GY90V6W,L   #1/QA^[3CS[C:E]@8\J7G7SQ=_*:OIR-5-'?5#*OHVV^!@>
MY/,.D
M
M
M
M   !%3SB_"7SM]Q[7Z[1(FYZ_9%G_P @EZ42;/#C]N6FOI*/H3,C1C\;J
M&Q3EG\-FY_PJM_8#3>K0'SAE'NK?\$3^9;G1]4]2_)KS\LH;+;F6   !HGXP
M_=IQY]QM2^P,>5+SKYXN_E-7TY&JFCOJAE7T;;? P/<GF'2
M
M
M
M                                              BIYQ?A+YV^X]K]
M=HD3<]?LBS_Y!+THDV>''[<M-?24?0F9&C'XW4   -BG+/X;-S_A5;^P&F]6
M@/G#*/=6_P"")_,MSH^J>I?DUY^64-EMS+    T3\8?NTX\^XVI?8&/*EYU\
M\7?RFKZ<C531WU0RKZ-MO@8'N3S#I
M
M
M
M                            14\XOPE\[?<>U^NT2)N>OV19_P#()>E$
MFSPX_;EIKZ2CZ$S(T8_&Z@  !L4Y9_#9N?\ "JW]@--ZM ?.&4>ZM_P1/YEN
M='U3U+\FO/RRALMN98   &B?C#]VG'GW&U+[ QY4O.OGB[^4U?3D:J:.^J&5
M?1MM\# ]R>8=(
M
M
M
M           "*GG%^$OG;[CVOUVB1-SU^R+/_D$O2B39X<?MRTU])1]"9D:,
M?C=0   V*<L_ALW/^%5O[ :;U: ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<RP
M  -$_&'[M.//N-J7V!CRI>=?/%W\IJ^G(U4T=]4,J^C;;X&![D\PZ0
M
M
M
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M;Y=94<OM$XVM"E"G!-MX0A%1BL7M>"2VO:^D^@?J/J
M
M
M
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MN83IUEOC).+7E3P:)GL[ZRS&WC>9?6I5[2:QC.G.,X279*+<7ZC/H'ZCZ@
M
M
M
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MTEQ13PJ0QZ*E.6$X=G%%)]#:/>'F'2@
M
M
M
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M6E._RZK3KV56/%"<)*49)]*DL4_U-Q](_2?6
M
M
M
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M_ALW/^%5O[ :;U: ^<,H]U;_ ((G\RW.CZIZE^37GY90V6W,L
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M0GC!=I.=)!
M
M
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MX*/::6O.+\)?.WW'M?KM$TYYZ_9%G_R"7I1,@_#C]N6FOI*/H3,C1C\;J
M&V7&4\9D=)Q='-5:%[$V]:QT&1IY2"O9QUFG)C8&SPW:]MKZTU:1BJCVR(K5
M3XFZ&25*U*QM*MM*4:\:-)Q<6U)/A6#36U/JPVG\Y&I;>SNKV_MLPA2J6,ZU
M:-2-11E3E%SEBIQDG%Q:WIK!K><Z9P9X_P"0[ZT''?'MA[F*KF4\;C??1B*B
M*YKJO;/&B*J?2:J=.IU[U-JJEY\KN[2QZ92P^_L(QCRXY876-&EE65RDUNC3
MIXX?L=J\J/@9/Q)\?,KW++Q[6J2+U[9<9FMCQO8J]G56P5,O'4=Z,Z?2C<B=
M55.BJJGU4=>:KH;KN4EU2A3E]]PQ^^>9><CN5U[BYY5"G/KIU:]/#=T1JJ/1
MTQ?3AM9R3/\ @)Q7?:]^ V/<=?L.:J,9-9QF9Q[%]51RUY\?5O/7JOK_ ,Z1
M%1/R+U4]VUYI9W2:5U1MZL.Q2A+[JDU_DG#9GX9-%W*<LLN[^UJM;$Y4ZL%^
MQ<(S?\)]S>1XVWP%Y)Q+9)M2V77-OA8B]M:RV?6LK-Z*K4BKV7Y#%HJ].GT[
MK.BJGY.JIUMAS2R>NU&_HUK>3Z5A4BO*UPR^Y!D69YX9-6V2=3([NTOJ:]C+
MBMZC\D9.=/[M5$3]TXKY%X\D[-TT[.X&/N1C+MJFZ7%2R*JHD=?,5%L8JQ)U
M_FQS.5/3\Z'<Y=G>49LL<NN*55]2>$EY8/"2]5$):@T7JO2L^'4%A<VT<<%.
M4<:;?5&K'BIR?8I-G@#U3F        ?=UK9L]IV;Q^QZSE;>&S>+G2>E?I2K
M'+&[HK7QO3UCGK3QJK)8I$=%+&Y6/:YJJB_+>6=KF%M.SO81J6TU@XM;/^1K
M>FMJ>U-,]+*,XS/(<QI9MD]:I;YA1EQ0G!X-=:?1*+6R49)QE%N,DTVBX_QQ
M\H,)S#4@UO8/JN$Y%JUW.EH-<L=#8X:T373Y'"+)_(G1.Y\U-7.DC:BO8KXT
M<K*^ZNT7<Z?F[RTXJF42>R7LJ;;V1GV="GN;V/!X8WWY3\X\NUY0CE.:<%OJ
MN$-L-T*ZBMM2ECN>]RI8N44G*+E%/AEH<(3>
M
M
M
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M[\F^;]#6UI'(\]G&&K:47MP48W,5[."6"51+\Y326YU(+AXHTYBD?D]
M
M
M
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M'.@
M    J]YY^:1Q3Q#OEW1-3U2[RO+A4=7V#/878Z.)P-++L?VRXC'7'8W+)F9J
M:(J6)8T9#'+^C:Y[FO1E6-?^*O2>CL_GD&46D\WG0V5:M*M&G2C4QVTX2X*G
M>./LY+",9>:G)J7#<OEEX,-;:[TS3U+G=]3R2G<>=0HUJ$ZM:=)K95G!5*7=
M*>^G&6,Y1\YJ*<>+BO\ OE=:_L$SG_>!0_ZJ'#_XT\L_L_7_ -;A_LY(?_\
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MYPD,
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MIOV-6-D.3?V4Z>^B;;X-&#//G[:-4?3=W\+(D<241*
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M,O/7GWJ7G1G?O[G:Z/MJK=I9I[([.%5J[6RI7E'';MC24I0I['.4YADS$"
M       &>OFG]\?+/\3-\_K3E2UVG?J_8?(Z'P<3+;F#]?<\^F+S^D5"X_Q2
M_#[QK_DS)_UAS!7W7'UKO/=Q^#@7VY*?9=E'[S4^'JDA3DR4P
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M5-QE3J)8X<7!449..[SHIQ3:3:;P.J'AG:
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M;B>'KD_:\GM T<KK1@]47O#7OZBVXUFO-HQETT[>+X(]#FZE18=XT1#(>)V
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M   &Q3EG\-FY_P *K?V TWJT!\X91[JW_!$_F6YT?5/4OR:\_+*&RVYE@
M:)^,/W:<>?<;4OL#'E2\Z^>+OY35].1JIH[ZH95]&VWP,#W)YAT@     !\3
M8]<P>W8/):WLF-K9?"9>L^I?H6V=T4T3NCFJCFJV2&>&1J/CD8K9(I&M>QS7
M-14^FSO+FPN87EG-T[FF\8R6]/\ 53W-/8UBFL#SLVRG+L\RZME.;485\OKP
M<9PDMC7X4T\'&2:E&24HM-)E)OD7X\9CA'/-LU7SY71,U9E;K^:>C5GK2]'2
MKA,PD;6LCR5>)%5DB(V.U&U7L1KDDCCL=I'5EOJ2UX)X0S.FEWD.AK=QP]JW
MO6^+V/%8-YY\UN5E_P N\R56BY5M-W$WW%5[XO?W-7#8JD5NE@HU(KBC@U*,
M8V'8$2     EWXA\WNXOWAFLYRVD>D[K:K4[SIY%;7PN;>J5\;FT5R^W##(Y
MS:]MR]K?95LCW=(40X+7NFUG66N\MHXYE;1;CAOG#?*':_91[<4O7$Y\B^8K
MT=J-91F-3#3N83C">+\VE6?FTZW4D]D*KV+A:E)X4TBZ4KJ:"@
M                   &1KS@_%GSM]^;?ZG2,?N>OVNY_P#+Y>C$W4\./V&Z
M:^C8^G,BH1,38; O$#\+? /\*=-^QJQLAR;^RG3WT3;?!HP9Y\_;1JCZ;N_A
M9$CB2B)0
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MNHOTOGLNYRNCC&UM(2;HV\'Y<..K/!.K6:4IM))0IQA3C)4DXB$
M &>OFG]\?+/\3-\_K3E2UVG?J_8?(Z'P<3+;F#]?<\^F+S^D5"X_Q2_#[QK_
M ),R?]8<P5]UQ]:[SW<?@X%]N2GV791^\U/AZI(4Y,E,
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MT*Y%:\>L-)JPOI\6>9;PTJC;\Z=/!]S5?6VDX2>UN<')^N1+$X4FX
M                     &1KS@_%GSM]^;?ZG2,?N>OVNY_\OEZ,3=3PX_8;
MIKZ-CZ<R*A$Q-AL"\0/PM\ _PITW[&K&R')O[*=/?1-M\&C!GGS]M&J/IN[^
M%D2.)*(E
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MHZKYLZEJ:CU16<GBU0H1;[BVI-K"G1@W@E@EQS]?4DN*;;W=O.Y(Y
M     ,]?-/[X^6?XF;Y_6G*EKM._5^P^1T/@XF6W,'Z^YY],7G](J%Q_BE^'
MWC7_ "9D_P"L.8*^ZX^M=Y[N/P<"^W)3[+LH_>:GP]4D*<F2F
M                >/W/0-,Y#QD>(W77<;L5"&;ZQ7BOQ.]VK/T[5FIVX7Q6
MZ<KV?1<Z*1BN;Z+U3T/0R[-<QRFL[C+JTZ-5K!N+WKJ:>*:\J9X6H-,9!JJS
M5CJ&TI75K&7%%36V+ZX234H-K8W%K%;'L/PZ/Q=Q]QM%;BT?5<7KWU]6K=GJ
M,EENVFL7K'%/?N2V;TD$;O5L:R>VU5541%53]F99WFN<2C+,J\ZO#N3P27:H
MI)8];PQ9\VG-&Z7TE"<-.65&U[WU[BFYRPW)SDY3:71'BP70CWQY9TP
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MS2UG=ZQSV35:O+AI4DVX6]"+?=4(8X>;!/:TEQU)3J-<4Y'9#M#@
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M.:Y$<US516N:J=45%3T5%0J^UAL>\TO336*VIG_0?Z
M         9&O.#\6?.WWYM_J=(Q^YZ_:[G_R^7HQ-U/#C]ANFOHV/IS(J$3$
MV&P+Q _"WP#_  ITW[&K&R')O[*=/?1-M\&C!GGS]M&J/IN[^%D2.)*(E
M                                                    !X_=^/\
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M?9=E'[S4^'JDA3DR4P
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M\:RL]4].U+$J)\>J_ A[,?&E>2FXY1D%.$$]DJUU*;:[8PHPX?)QR\I.V5>
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M; O$#\+? /\ "G3?L:L;(<F_LIT]]$VWP:,&>?/VT:H^F[OX61(XDHB4
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M6MKI73UU=W=.KEM.YJ2KNFY1G4K5Z:@N[A!)<-)2VK'SEMPW3,)J*_
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MD5_1J7;7YF>-.MLWX4YJ,I8=+@I1[3K1X1W
M       .'[_Y&\/<;/GJ;!N-&QEX%<U^"P*.SF69,WNZU[,./]V#&S_1_DVY
M(/R?G3KTN5:1U!G"52TMY*@_9S\R.'6G+!R7N5(CG4_-?0>DI2H9I?TYWT=]
M&C[]53_%DH8QIOLJ2A]]$3ME^85BXWR1:?QQ?N,7K[-W9<U7QSV_F63%XNME
M$=U_*B7$Z?G4[FSY45FE+,+R,7TJG!R_RI./H$)9OXI;.$G#(<IJU(]$[BK&
MF_5ITXU/A4<GO^?O+DZO;0UKC^A&Y$1CI,=G[EF-4=UZI*[8X:[NK>B>L*_E
M7\W3W:7*S(8X.K6NI/W4$ON=VW]\XFY\3NN:C:MK/*Z4'NQA7E)>KWZC]V/_
M "?BK>>_-$"N6;$<?74=V]&V,)FV=G15Z]BU-FK+U<B_SNY/3T/V3Y7:=EZV
MI=Q\DX?JTV?/1\3/,"FVYT,KJ)_C4:RP\G#<1^_B=#P/S"\S'(QFS\;8RW$Y
M522? YRUCI(VJ[JCV5,A3RC9E:ST[5FCZKZ]R? \JZY46[3=E>3B^J<%+[\7
M'#[C\AU.6>*6_C)1SG*:-2'3*C6E3:V[U&<:F.SHXXXO;BMQ)31_,WA+<)(:
MM[+WM*R$O1J0;9494I+)V]7]N9I37L5#"B]>C[$M?N_,B^AQV9<O-29>G.E3
MC<TETTGB_P!HU&3?9%2)<T[S_P"7F?2C1N:]3+[J71<QX88]/OL'.FEU.<H8
M]6.PE-3N4\C5@O8^W6O4K4;9JURG/%9JV(G>K98+$+GQ31N3X.:JHIQ-2G4I
M3=.K%QJ1>#3333ZFGM1,U"XH75&-Q:SA4MYK&,HM2C)/I4DVFNU,_2?@?N
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MWA=_QIHW_<WRA_LKIO\ W99?Q!<?\I;D_DKDC_7_ /ZP^0]YWW]C?ZJOV/\
MTTVW/[3^ROVC_K(_:'[-_;F0O?4?KWU&#WO:[?=]EG=U[&]+H>$/5.I]2_\
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M.NQWH^>5S(6*O17=RM:ONY%IW,]07'<6$/>UZZ<MD(>5]?5%8M]6&+.)UMS
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M,L   #1/QA^[3CS[C:E]@8\J7G7SQ=_*:OIR-5-'?5#*OHVV^!@>Y/,.D
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MG)MK$S:YE:NCKW7N;:QITYT:.87M2K"G)IRA!O"$9..";C!13:Z4=8.N.'
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MGL79%;HKLBDBXN0Z;R+3%BLNR"UHVMHL,5".#DULXIRVRG+VTW*7:>K/A/;
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M&6O>:F>:H4N*UKWTX47C_P"[T,*%#L6-*G"3PV<3;V[SOY(1%P
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MD^3%+*J5'6&K*2EFLTIV]O-;*">ZI4BUMK-;8Q:PI+:_?,.[L((H+1@
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MGX?^74-3YW+4V;4U+),OFN",ML:MS@I1BUTQI)JI)/8Y.FFI1<D7#$ %\0
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MO>"Q[<"I_C1SEY7R,NK-2P>8YA:6^]+'";NFMKQ>RV>*6+PQQ6&)IY-23&\
M            $5/.+\)?.WW'M?KM$B;GK]D6?_()>E$FSPX_;EIKZ2CZ$S(T
M8_&Z@  !L4Y9_#9N?\*K?V TWJT!\X91[JW_  1/YEN='U3U+\FO/RRALMN9
M8   &B?C#]VG'GW&U+[ QY4O.OGB[^4U?3D:J:.^J&5?1MM\# ]R>8=(
M         "A3R:PR8'GGDZBC48D^QOS/1.GJNQTZFPN=]'TZO=E.[\_KZ^I:
M'1MQ\:TO95.JCP?P;=/\DS/YOY>LMYEYQ;I8<5VZO\/"-?'U>\Q.%'3$;@
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MR3.ZY#Z1AJG75*XNX\66Y='XS-/=*<6E1@_+4:FT]DHTY)[R[<K@:'@
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M0>EJ&C=)V>GZ27>T:2=62]G6GYU67;C-M1VO"*BMR1TP\8Z\
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M=U2^[Y#-#Q^Z?A3S/3NJJ<?/K4+FTJ/#HI3IUJ*Q[>^KO#L>'278EX3.X
M %.'SC?W:\-??C/_ &!&4P\9_P!6,E^7U?@D7\\ GUOU!]&T?AF9_C/0U$/>
M<7Z#E>4^1M(XYPB*F2W39L/KT$W8Y[*;,E=B@LY&=K$<Y*N-JN?8E5$7MBC<
MOY#W]*Z?N]5ZDL=-V/\ .KZZIT4]ZCQR2E-^UA'&<NJ,6SFM9ZGLM%Z3S'5F
M8_S/+[.K7DL<')TX.4::Q]E4EA"*Z922-F>I:MA-(U?7=.UNFRA@-6PN-P&&
MILZ=*^.Q52*E48YS6M]R3V845[U3J]ZJY?55-JLGRJQR+*K;)<L@J>7VE"%*
MG'JA3BHQ7:\%M?2\6]Y_/SGF=9CJ/.;O/\WJ.KFE[<5*]6;]E4J2<Y/L6+>"
MW)8);$>A/1/*       !0E\X[=);&X\,\=QR]L.(UG8-TMP-D:OO2[%E(<'C
MI9H47O3ZLS5[21N7HB^\]$Z]%Z9_>,_.YU,ZR73D7A"C:UKF2QWNM45*#:]K
MW$\'[:1IQX!-/0I9!J#5<HXU*]Y0M(O#<J%-UJB3W><[BFY+VL>M%+A28T(
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M_@PTQ_75_P#P5+]<?X^]7_V?RW^&K?K#_<Y<:_VR[Q_F# ?X0?X,-,?UU?\
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M4*C_  X$?^&2V577EU<26*I974P?5*5:A%?Y/$BWT@(O8
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MIL)YKIG,<KIQ4ZES87%)1>U2=2E."323>#;P>Q^0VQ&X1_.X
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MRZA+RNIWGJ>;47X3&WQH6=2UYZWE>?K;FPLZD?(J2I>KYU*75U=!8F6/*H@
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M<.4O,.3$+Z*VV.<6U9OI49PKV[6Y['*O'%8K:D\=F#TLFG)D&
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MIXUU&:OCZTE5C?9#KNC%NA.E4L*LL-D90E*XMXX]<U.Y:71W;ZR[<O(9T@
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M^C:D_P#)4EZI5?DOG4,CYE99<59<-"M5E;RZO?X2IPQ[%4E!^H7N%8S28
M             %<OS"-IBBP7'VDQO1TUW+9#:;4:*G6&+&4W8G'O>G\KI9?E
M[*-7X?HG$N<J;*3N;O,FO-C3C37:Y/BE]SACCY450\4F<PAEN5Z>B\:E2O.X
MDNI4X]U!OW3JU,/<LX?X(:])E.9+N;5COJ^L:EE;7NI_);=R<]/$UX7?^U+4
MM67)_P#TU.EYG7:H:>C;8^?6KQ6'9%.3?J-17JD=>&O*I7NOJF8-/NK.QJ2Q
M]O4<:45ZL95'^Q9<45^+Z                  %"'SD-7?7W/A+=&L<L>7U
MC:M7ED1CU;&_7,KC<K R23N5C73-VF16-Z-5>QR]7=%[<_?&AE3IYWD>=I>;
M6M:]!O#=W-2%1)O=M[^6"Z<'OPV:<^ +.8U=/ZBT\VN.A>6UPEBMJKTZE*32
MW[/BT<7M2XH[L=M+Q2<T'   )/>&&[,X^\IN$-CED2&L[>*&N7)G.[(X:6Z0
MV=.N3S.[F(D->OGG2.55Z(C>O1>G0E+DGGBT]S6R+,IOAIN_A1D^A1N5*VDW
MV)56WV(ASQ!Z=EJGDMJ/*8+BK++9UX+>W.T<;J,5OVRE145VOH->1L081
M           BIYQ?A+YV^X]K]=HD3<]?LBS_ .02]*)-GAQ^W+37TE'T)F1H
MQ^-U   #8IRS^&S<_P"%5O[ :;U: ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<R
MP   -$_&'[M.//N-J7V!CRI>=?/%W\IJ^G(U4T=]4,J^C;;X&![D\PZ0
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M*N9VB."2/OQVB8FZLL$-E.OO0R;)GZ;&Q*WT?!1LL=Z/3K3[Q;\PZ63Z9I:
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MK4E-^63;P\BQP1JMDV5V^1Y1:Y-:?S:UMZ=*/1BJ<5%-]KPQ?6VS[Q\IZ0
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M)4=OJ=*+H>!K4:ROFU<Y%5:5+-,JJPBNNM0G"O'[E*-?9OZ=R9FY,T#7
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M\@EZ42;/#C]N6FOI*/H3,C1C\;J   &Q3EG\-FY_PJM_8#3>K0'SAE'NK?\
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MS&7LL%>+D9RREHO)GG6<0PU+?06*:VT*.R4:76IR>$ZN[!J$&L:;;F&1^3R
M                    9#?,KBMW#ODIRII\4#H,1-L4^SZW]!60KKVVM;L&
M.@K*O_&Q8OZ^^DKORR5G)\4,=^=.DWHSF;FV30CPV<KEUZ.S!=S<>_04>M4^
M-TL>N#-W/#_K5:^Y19)GTY*5_&T5O<;<7W]M[Q.4NIU.!5DOQ:D2,)%I,@
M!,#P8YS;P)Y%:?L62M?5M1V=S]&W5SG(R&'!;#/69!DYG.7MCBP6<KU+LKNB
MN]B"1C?5Y,G(?7BY?\R+/,KJ?#D]UC:W/4J59QPF^I4JJIU9/?P0DEO(&\27
M+:7,[E1?Y39PX\]LTKRTP6+=:@I-TUTMUJ,JM&*V+CG"3]::T#78PX
M      (J><7X2^=ON/:_7:)$W/7[(L_^02]*)-GAQ^W+37TE'T)F1HQ^-U
M #8IRS^&S<_X56_L!IO5H#YPRCW5O^")_,MSH^J>I?DUY^64-EMS+    T3\
M8?NTX\^XVI?8&/*EYU\\7?RFKZ<C531WU0RKZ-MO@8'N3S#I           ?
MCR.0I8G'WLKDK,5/'8RG9R%^Y.[MAJTJ<+[-JS,[U[8H((W.<OY$0_92I5*]
M6-"BG*M.2C%+>VW@DNUO8?HNKJWL;6I>W<U3M:-.4YR>Z,()RE)]B2;?8C/C
MRWO]KD_D7:MVL^XV+,9*1<;7E]'4\-4:VEAZCFH][&20XZO'[G:O:Z57._*6
MLR'*X9+E%#+88<5.'G-=,WMF_5DWAV8(RYUQJ>MK'5=[J&KBH7%9]W%^QI1P
MA2CO:34(QXL-CEB^DYR>N<H   2N\,]&_IAS9A\A/%[F-TFG:VNTKD5&+<K=
ME+"QH]/1)F96Y'.U/YS:[OS'#<P\S_1^G*E*+PK7,E27D>V?J<*<?V2)LY Z
M<_3W,.A=58XVF74Y7,NKBCA"DL>M5)QFETJ#+LBN)H8         ?/RV)QF>
MQ>2PF:H5,KA\Q1MXS*XR_!'9I9#'7H'UKE*W7E:Z*>M9KRN8]CD5'-<J*?/>
M6EKF%I5L;ZG"K9UJ<H5(32E&<))QE&2>QQDFTT]Z9]5C?7F67M',<OJSH7]O
M5C4IU(-QG"I!J4)QDMJE&2336U-8F;#S?\ MBX%R.4Y'XQHWMAX7MSNLV(8O
M?OYCCE\[U5U'-+TDGM:TQZHVKD7*Y8T5(;2I(C)K&9?/3P^9EH"YJZETO"I<
MZ)G+B:6,ZEFW[&KO<J..RG6>.&R%5\7#.IKMX<O%!E7,VUHZ2UC4IVG,*$>&
M+?#"E?I+U]+<HW#6VI022EMJ44X\5.E6<5A+@  FQPO\P/R7X5KU,1C]OCWC
M5Z;(X:^M<B06-CJU:\?HR"AEFVZ6R4(8HOHQ11W?J\:(B)%T1$)PT3XA^9VB
M*<+.WO%?95!)*C>)UHQ2Z(5.*-:"2V1BJG MGFX+ KMS"\+?*#F'5G?75@\M
MSFHVY7%BXT)2D][G2X9V\VWME)TN\D\<9XO$L-TWYQ^LS011\@\+9W'6F)VS
MW--V7'YF"PO;U]V+&YNG@9*:*[T]M;<_1/7O7^2EC,E\:&5SIJ.HLDN*=5;Y
M6U:%1/M4*L:3CY.\EUX]!5;/_ 'G%.K*>EM0VU6B]T;JWG2E'L=2C.LI=?$J
M<.KAZ3JO^]^\:O\ Y(YR_P"C6@__ +F'6?XQN67_ ,#GW\#:?[:<3_@.YO?U
MEIO_ %B]_P#V\YYMGSCM!K1RMT7AG;\W*J/;!)MFPX75XVJKY&QRRP8>#<'/
M1K.USHTD;U55:CTZ(]><S?QGZ?I1:R')+RO/;@[BM3H+IP;5-7&.S!M)KI7$
MO7'59'X ]3UI1>I-06%O#9Q*VH5;A[EBDZKM<-N*4G%X+"7"_6D">8/F5^3?
M*D%G%XS8*'%NOV6.BDH<=U[&-RL\*]>GUC:KMF]L,,W151SJ4U)CD^+" -9>
M)OFCJRG*UM;BGE67R6#A9IPJ-=M>4I5D^VG*FGTQ+.:"\(7)W152%[>6M7.L
MT@\5.^E&I33]K;0C"@UU*K"JUT2("3SSVIYK5J:6S9LRR3V+$\CYIYYYGK)+
M--+(KI)999'*YSG*JN5>J^I7RI4J5:DJM63E5DVVVVVVWBVV]K;>UM[6RS]*
ME3HTXT:,8PHPBHQC%)**2P226Q)+8DMB1_$_ _,G3X:>$NY>3FQ5LWEX<AK/
M#F)NJFP[=[216,U)5>Q9M;U+WV.9;RD_7LFL]CZU%G<Y_?*D<$D\\EN1V=<T
M<RC?7D:EKHNC/WZXPP=5Q:QHV^.R4WNE/!PI+%RQEPTY5L\0'B*R#DYE,\NL
M)4KS7]>G[Q:XXQHJ2>%>ZX7C&FM\:>*J5G@H\,.*I#3_ *5I6K<=:MA-*TK"
M4M=U?7:4>/Q&(Q\:LKUJ[%5SG.<Y7S6;5F9[I9YY7/FGF>Z21SGN<Y=3,DR3
M*=-Y30R/(Z$+;*K:"A3IP6"BE]^4I/&4I2;E.3<I-R;9C7J'4.=:KSJXU%J*
MXJ7><W=1SJU9O&4I/[BC&*2C"$4HPBE""44DO4'JGC        @=YK^%&O>4
M6O19W!2T=<YAURBM;7=BLI)'CLYCHY);#=8V=U>*:9<>LTSWUK+&/EI2O<J-
M?&^2-T!<\.1^7<U,N5_8.G;:RMJ?#1K2Q4*L$V^XKX)O@Q;<)I.5.3;2<7*+
MLQX=_$1FO)G-7EN9*K=Z"NZO%7H1P=2C4:4?C%OQ-+CP252FVHU8I)N,HQDL
MQV]:'M_&FTY;2M[U_(ZSL^#L+6R.)R<*Q3Q+T[HIX7HKH+E*U$J206(7/@GB
M<CXW.:J*N7.?9!G.F,UK9)G]O4M<TH2PG3FL&NII[I1DML9Q;C*+4HMIIFQF
MF]39#K#):&H=-75*\R:YAQ4ZM-XI]::WQG%^;.$DIPDG&45)-'D3R#W#HW&O
M+G)G#V<38^,MUSVFY9?;2>7$7%95R$<3E?'7RV+G;-B\S4:]>OLVX9HNOKVG
M2:9UAJ?1E_\ I+2]]<65WLQ=.6$9I;E4@\:=2/M:D91[#D]7Z%T?K[+?T3K'
M+K7,+';PJK#&4&]CE2J+"I2DULXZ<X2PZ2SCC7YOW*F#@KTN4..=7WYD2-C?
MF,!?LZ3F9F]K46Q<A^J9_"V;".ZKVP5J4:IT3HW^4MHM,>,;5EA3C0U5EMKF
M"6SO*4Y6U1]LEPU:4GV1A371@MY3K5_@.T5F565QHS-KW*Y2VJE6A&[I+VL'
MQ4:T8]&,ZE62WXO<2IQ?S@^ Y8.[-<<\OX^ST;^BQ=#2\O!U7N[T^L6]RPDG
M1OIT7VO7JOPZ>LL6OC)Y?3AC>Y;G-.KU0A;5%V[97-)_Y.WL(4O/ 7S/A4PR
M_-LAJT>NI.[I/L\V-K67^5L[>C_>2^<%X_Q5G.P_'?,5ZW]+M@R6-TK%5E^B
MJM[K57=LS*WJ_HB_H5Z(O7UZ=%_*Z\9/+V%/&SRW.:E;JG"VIK]M&YJ/_)_6
M/QM/ 7S1G5X;_-L@I4.NG4NZDOVLK2DMWM^SM(P\C_.#Y&R]>Q2XOXNUK2_=
MCDA9F=HRUO<LE%W)T9;ITJM37,74LQ_%&SMO1=?BCD]"+-2^,G4MY3E0TKE5
MK98IKO*]25S->VC&,:,(R75)58]:9,FDO 5I*QJQN-9YS>9A@TW2MZ4;2F^N
M,YRE7J2B^N#HRZFBL?E/F[ECFS+IF^4M[SVX6XY))*E?(66Q8C&++_QC</@:
M+*N$P\<G\YM6O$COR]2KNJ]<ZNUQ>?'M5W]Q>5DVXJ<L*<,=_=THJ-*FGTJ$
M(X])<717+G0_+NP_1VB\LM;"@TE*4(XU:F&[O:TW*M5:Z'4G)KH.5G*':GH=
M4U/9=YV+$ZEI^$R.Q[)G;D='$X;%5GVKMRS)UZ-9&Q.C(XV(KY)'JV.*-KGO
M<UC55/1RG*,SS[,J.49-0J7.9W$U"G3IIRE*3ZET);VW@HI.4FDFSRL[SS*-
M-Y57SS/KFE:91;4W.K5J2480BNMO>V\%&*QE*348IR:3LK\@_!_$>,_B#C-T
MVY\>7YGV+?\ 5:69M5K+Y<1J>)NXK8+<NL8AK'I7O6$GIQK;NJCO<D9V0](D
M5TMF^8G(NSY8<G*6=YPU6UM<YC0C4E&3=.WIRIU9.A3PV2>,8]Y5VXM<,,(+
M&=0N5OB-ON<'/BMI[(DZ'+ZTRNYG2C**56YJPJ4(JXJXKBA'"4E2HIKAB^*I
MC-I0JS*IETBU;Y0/XE=W_@;LO]?N,RV7@Y^TV^^@:W]+LBD_CQ^R'+?_ ,DM
M_P"A9@:.C2@R7    !3A\XW]VO#7WXS_ -@1E,/&?]6,E^7U?@D7\\ GUOU!
M]&T?AF9_C/0U$+R/DQ?^9'_L>_\ %(O;X*/_ #-_X=_]<9O_ /J"_P#E'_Q3
M_P"W%Y!>TS?            *NO//P(K\\1VN5N*H:>-Y=H4NF8Q#W,JX_D6E
M0K*VK ^9W;!2VRO%&V&M9D5L-B-&PSN:C8Y8ZK<_O#]3U]">K=)QA2UC3A[Y
M3>$87D81\U-[HW"2483>$9K"%1I*,HW.\,WB<J\LYPT1K:52MH2K4]ZJK&4[
M"<Y><TM\[:3;E4IQQE"6-2FFW*$\Y&:PN7UO+Y+ ;!C+V%S>'N6,=E<3DZLU
M+(8^]5D=%8J7*MAC)H)X9&JCFN1%13-B^L;S+;RKE^84JE"^HS<*E.<7&<)1
M>#C*+P::>],UFR[,;#-[&CFF5UJ5QEUQ3C4IU:<E.$X26,91E%M2BUM33/EG
MRGV'9>(_(+F3@K(KD>+=]SFKMEF;/=Q,4T=[7<I(C?;[LIKF2CMX6_)[2JUL
MDD"RQHO5CVKT5.TT?S$UIH*Y^,Z4S"O:IRQE334J,WN\^C-2I3>&Q2<>)>Q:
M>TX#77*W0',JT^*:TRRVO7&.$*K3A7IK''WNO3<:T%CM<8SX9>RBUL+.>._G
M$;E0AK5.4^)<%LCFHV.;-:9FK>LV5:UW1;$F%RM?8*EJPYG\IK+-6-7^J(U/
MHI:/3GC,SJWA&CJO*+>Y:V.K;594)>5TZBK1D\-Z4Z:QW8+84YU7X!]/W52=
M?1>>7-HGM5&[I1N(^Y56G*A*,<=S=.I+#8W)[22%#YP/CU)68[*<?<RT[:]/
M<@H8G2,E6;]%JKV6K&]8J5_1ZJGK"WT1%_+T22[?QD<NI4T[K+LZA6Z5"G:S
M7[9W5-O]JOU")+GP&<U(57&SS73]2AT.=6\IR]6,;.HELP]F^KHQ?XLS\X7@
MN"#NU[C3EG*6NU?T.9KZ?@H.[JWM3ZS1VG8Y.U6]>J^UZ*B>B]>J?HO?&5H.
MG3QR[*\WJU>JHK>DONQKUG_DGT9?X">9-2KAFN<9'1HX[Z4KJM+#W,[:@O\
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MQ<,7U-,OIX<M*O)=&3SVXCPWF:5>-8K!]Q2QA26W\:3J33Z8SB^IDUB.2P@
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MCVFC^C]=Z/U]EBS?1V86U_8X+B=*:<Z;DL5&K3>%2C/#V%6$)+J.<G-G6
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MWM+KZ5TAD&B\L65:?H1HT-\I;ZE27X]2;VREU>QBO-@HQ22]Z>6=,
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M9PS.]:OM2)8JK*/F4G_H(/'!]'>2QF_8\";B2M.&)K
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MC4YN/^3)2],A#./"U9SFYY#FU2G#HA<4E4?\)3E3^"9R2_X"<OUU<M'8./\
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M:F6"$5%H0
M
M
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MDHQ2Z$DDD?L/UG[P
M
M
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MU>J*GHJ%YHRC.*G!IQ:Q36U-/I1G1*,H2<)IJ:>#3V--;TUT-'^S_3\0
M14\XOPE\[?<>U^NT2)N>OV19_P#()>E$FSPX_;EIKZ2CZ$S(T8_&Z@  !L4Y
M9_#9N?\ "JW]@--ZM ?.&4>ZM_P1/YEN='U3U+\FO/RRALMN98   &B?C#]V
MG'GW&U+[ QY4O.OGB[^4U?3D:J:.^J&5?1MM\# ]R>8=(    #\]NY4Q]6S?
MOVJ]&C3@EM7+EN>*M5J5H&.EGL6;$SF0P00Q-5SWN5&M:BJJ]#\Z=.I5FJ5*
M+E5DTDDL6V]B22VMOH2/U5Z]"UHSN;F<*=O3BY2G)J,8Q2Q<I2>"22VMMI);
M652>3/EU/N#<AH'%]N>GJCTFIYW9XT?!<V6)R(R6CC.YK)Z.$?\ 2;(]>V6V
MU>WZ,2N26<=&Z"CE[AFN=14KY8.%/>J;Z)2Z)3ZENCOVRPX:4<W^>=3/55TQ
MHZ<J>2O&%:X6*E<+<X4]SA1>U2>R55;/-ABIP")3*Q@    _;C<=?S&0HXG%
MU)[^2R5NO1H4JL;I;%NY:E;!7KP1MZN?+-*]&M3\JJ?KK5J5O2E7KR4:,(N4
MF]B22Q;?8D?1:6ES?W5.RLX2JW=:<80A%8RE*3PC%+I;;21>KXZ<*T^%M#KX
MN9L$^V9KV,EMN1BZ/22_[2I#BZTW3N?CL.R1T<7P1\CI)>B>XJ)675NHZFHL
MT=:.*L:>,:47^+TR:_&GO?4L(]!I%RIY>V_+[34;.HHRSNXPJ7,UMQGALIQ?
M3"DFXQZ&W*>"X\#OQRQ)P
M
M
M                                            !0S\S#PL?A[F6\D>
M+,0YV'O2NN\L:]CXD_\ =60GE:V3>:%:/HY<?D9I$7*-8U5@G5;2]8Y)W14"
M\3W)&5E6K<R]*4<;*H^*_HP7YN;>VZC%>PFW[^DO-E[Z_-E4<-,_!_XA8W]"
MARDUI72OZ4>#+:\W^<A%;+.<G[.FE_)VWY\,**\Z--3I5*1&AH     !9%XB
M_,3WWQ_;C](W^/(\B<2Q+%7JT7V6/VK3*Z.:U5UB]=>UE[&11?#%VI60-5K4
M@EK)WI)9;D]XC]0<O%3R+4"J9EI!8*,.)=_;+_02D\)02_<)R45@N[G2\[BJ
M1SV\*.F.:+JZCTNZ64ZYEC*4U%JVNY;_ .40@L85&]]Q3BYO%]Y"L^'AT0\4
M<Q<;<W:M7W'C+:\;M&&E[&6?JLBQ9'$VW-5RX_.8JPD61P^08B=?:L1L<]G1
M[.YCFN71S26L],ZYRF.=:7NZ5U9/9+A>$Z<OQ*M-X3IS]K-)M><L8M-Y3:WT
M#J[EUG4\@UC95K+,(XN/$L:=6/X]&K'&%6#_ !H2:3QC+"2:733J#CP  "*G
MG%^$OG;[CVOUVB1-SU^R+/\ Y!+THDV>''[<M-?24?0F9&C'XW4   -BG+/X
M;-S_ (56_L!IO5H#YPRCW5O^")_,MSH^J>I?DUY^64-EMS+    T3\8?NTX\
M^XVI?8&/*EYU\\7?RFKZ<C531WU0RKZ-MO@8'N3S#I   #F7)O+VA\1X=<MN
M69BJ22QR/QN&K*RSG<P^/HBQ8W&H]LDK4>Y&NE>K*\2N3W)&HI[.39!FF?7'
M<9?3<DGYTWLA#W4NCL2QD^A,X_6&NM-:&L/CN?W$83:;ITHX2K56NBG3QQ>W
M!.3PA'%<4D5 \[>36Z<T69<8BOUO1H9^^GK-*=RNO>U)WPV]AMM[%R=I'-1S
M8^C:T*HG:Q7HLCI]TSHW+M.P5;\]F;6VHUNQWJFO8KK?KGTO#8J)\R>;^H.8
M%65FL;33D98PMX/U^#Q4J\MG>2W-1V4X-+ABY)S<:CL2(P     "V#PY\<GZ
MI3K\K;O06/9LE65=3Q%N%6RZ_B[42M?EK4<K4?#F,I ]6QLZ(M>JY>JJ^9S8
MH,Y@ZN5]4>1Y;+&S@_?9I[)R3]:L-\(O:W[*79%.5V>0O*B624(:UU%2PS>M
M#^34I+;1IR6#JR36*JU$\(K?"FWCYTVH6 $5EGP
M
M
M
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M]<>P>$14\XOPE\[?<>U^NT2)N>OV19_\@EZ42;/#C]N6FOI*/H3,C1C\;J
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M&M5BU^;6^G!K&H\)OWO!5+2"%"Y8
M
M
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MF-%K&3P=1*/FSL^1$1$1$1$1.B(GHB(GP1$_(B$+EQ4DE@MQ_P!
M
M
M
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MR(L=+NEGVJU3NM0QPE"ELE1MWT/;LJU8[^/UD)>L3<54<XR-2QH
M
M
M
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M)*/\JDDJE>>$JU3W4L%A'':H048+?ACBWUP\$[D
M
M
M
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M#_0
M
M
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ME"X[JMY?,V=.\C^J*U5:Y%1R*J*BIT5%3T5%1?5%12/&FG@]Y**::Q6X_P"
M   &Q3EG\-FY_P *K?V TWJT!\X91[JW_!$_F6YT?5/4OR:\_+*&RVYE@
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M18/2W*+06DG&ME]C"M?QW5KCWZICUQXEP0?;3A!G>CER2P
M
M
M
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MK"1IU]6*WK^3H7$R6O+)*]M7MTIRM7#AXMSX,,,<,-^&W# H3JK+J6K<MO\
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M><I>DV=]EN09%DT>')[*TM8_Z&C3I^A%;^D](?&>L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
)        ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
